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ABSTRACT
GAT107 IMPROVES SURVIVAL BY ATTENUATING HYPEROXIA-COMPROMISED
HOST DEFENSE IN BACTERIAL CLEARANCE IN THE LUNGS VIA ALLEVIATING THE
REDOX IMBALANCE IN MACROPHAGES
Alex G. Gauthier
Prolonged exposure to hyperoxia can compromise macrophage bacterial clearance
functions, contributing to the increased susceptibility to pulmonary infections
observed in hospital and ventilator-associated pneumonia (HAP/VAP). Previously
studies in our lab demonstrate that activation of the α7 nicotinic acetylcholine
receptor (α7nAChR) has protective effects against proinflammatory lung injury in
animals subjected to prolonged hyperoxic exposure and bacterial infections. In this
study, we demonstrated that administration of GAT107, an α7nAChR agonistic
positive allosteric modulator (ago-PAM), improved survival by attenuating
hyperoxia-compromised bacterial clearing functions of mice with Pseudomonas
aeruginosa (PA) lung infection. GAT107 decreased the bacterial burden in mice lungs
by attenuating the hyperoxia-compromised phagocytic functions of both cultured
macrophages, RAW 264.7 cells, and those isolated from mice. In hyperoxia-exposed
RAW macrophages, GAT107 treatment attenuated oxidation of F-actin, a critical
cytoskeletal component involved in phagocytosis. In hyperoxia-compromised mice
with PA lung infection, GAT107 ameliorated hyperoxia-induced oxidative stress
levels and increased the antioxidant oxidant potential in lung tissues and also in
cultured macrophages. GAT107 induced the activation of the master antioxidant
transcription factor, Nrf2, and significantly increased the levels of its down-stream
antioxidant heme oxygenase-1 (HO-1) protein in macrophages. In macrophages,

hyperoxia induced mitochondrial membrane perturbation and also elevated
mitochondrial superoxide (mitoSOX) levels, which was attenuated with GAT107
treatment. GAT107 decreased mitoSOX via attenuating hyperoxia-compromised
manganese superoxide dismutase (MnSOD) activity and had no effect on its total
protein levels. MnSOD activity was found to be strongly correlated with the extent of
cysteine glutathionylation, which was attenuated in GAT107-treated macrophages.
Thus, these data suggest that GAT107 provides protective effects against PA
infection-induced inflammatory lung injury via attenuating hyperoxia-impaired
macrophage function via restoring redox balance. GAT107-elicited efficacy in
macrophage functions under hyperoxic conditions is through restoring the redox
imbalance mediated partly by mitochondrial stress and MnSOD functions. Thus,
GAT107 may be a potential therapeutic agent acting to improve host defense
functions in the subjects exposed to prolonged periods of hyperoxia, such as VAP,
HAP, and COVID-19.
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1. INTRODUCTION
1.1. Hyperoxia-Induced Compromise of Host Defense Functions and
Ventilator-Associated Pneumonia
Oxygen therapy, using concentrations of supplemental oxygen up to 100%
(hyperoxia), is a routine treatment for intensive care units (ICU) patients, surgical
patients, pre-term neonates, patients with acute lung injury (ALI) / acute respiratory
distress syndrome (ARDS), patients requiring home oxygen therapy care such as
those with chronic obstructive pulmonary disorder (COPD), and in patients receiving
supportive care for airway-associated infections, such as the novel COVID-19
coronavirus (Branson, 2018; Magnet et al., 2017; Renda et al., 2018; Walsh and
Smallwood, 2017; Wang et al., 2020). Although oxygen therapy is a lifesaving
intervention, prolonged exposure to hyperoxia to patients can compromise lung host
defense and cause inflammatory acute lung injury (ALI) (Kallet and Matthay, 2013;
Pham et al., 2017). Consequently, patients with compromised host defense and
exposed to hyperoxia, experience a higher susceptibility to pulmonary bacterial
infections that cause ventilator-associated pneumonia (VAP) and hospital-acquired
pneumonia (HAP) (Bassi et al., 2014; Oliveira et al., 2014). Approximately one-third
of all MV ICU patients develop VAP, which has a 4.6% mortality rate (Rello, 2005;
Rello et al., 2002; Spalding et al., 2017). Oftentimes, Medicaid denies insurance claim
reimbursement for these patients since the disease was acquired under hospital care,
placing increased financial burden on both the patient and the hospital (Rello et al.,
2002; Spalding et al., 2017). VAP patients have to pay large amounts of out-of-pockets
expenses to cover the increased medical costs for care, which ranges from about
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$20,000 to $100,000 and averages approximately $40,000 per case of VAP (Kollef et
al., 2012; Rello et al., 2002; Zimlichman et al., 2013).
The antimicrobial functions of the innate immune defense system of the lung is
complex and depends on the type of pathogen or pathogen/damage associated
molecular pattern (P/DAMP) and their location within the airways (Martin and
Frevert, 2005). Larger particle pathogens that enter the nasopharynx or conducting
airways can become trapped in mucociliary surfaces where they can be expelled
through a mucociliary clearance mechanism (Martin and Frevert, 2005). Smaller
substances of 1µm diameter or less can be deposited into the deeper conducting
airways of the bronchioles and alveoli. In the alveoli, the leukocyte population is
composed of 95% macrophages (60-70% alveolar and 30-40% are interstitial
macrophages), 1-4% lymphocytes, and 1% neutrophils (Martin and Frevert, 2005;
Tan and Krasnow, 2016). Alveolar macrophages are a first line of defense against
invading pathogens that enter the distal airways (Allard et al., 2018; Byrne et al.,
2015; Craven et al., 1986). The alveolar environment is enriched with high levels of
opsonizing immunoglobulins (e.g. IgG and IgA) and lipid binding protein, which
augment the host defense response of alveolar macrophages to phagocytose invading
pathogens (Martin and Frevert, 2005).
It is estimated that average adult intake of total air is approximately 10,000 L per day,
which contains 2,100 L of oxygen (Hartl et al., 2018). In patients receiving oxygen
therapy, oxygen concentrations often reach 100%, increasing the amount of inhaled
oxygen to 10,000 L. Unlike other organs that rely on oxygenation via perfusion by
circulating blood, the alveolar macrophages are in direct contact with these hyperoxic
2

levels of oxygen. Alveolar macrophages are derived from yolk-sac fetal monocytes,
are self-renewing, and can be replenished by interstitial macrophage proliferation
and differentiation (Tan and Krasnow, 2016). In response to the exposure to
hyperoxia, the amounts of alveolar macrophage do not change due to the activation
of cell survival pathways (Baleeiro et al., 2003; Monick et al., 2008; Petrache et al.,
1999). However, in mice and ex vivo alveolar macrophage cultures, prolonged
exposure to hyperoxia impairs the phagocytosis of bacteria known to produce VAP,
such as Staphylococcus aureus and Pseudomonas aeruginosa, and certain bacteria
from the Enterobacteriaceae family (Baleeiro et al., 2003; Barbier et al., 2013; Bassi
et al., 2014; Chastre and Fagon, 2002).
Pseudomonas aeruginosa (PA)-induced pneumonia has the highest associated-death
rates (87%) when compared to all other bacterial pneumonias (55%) (Chastre and
Fagon, 2002; Cotoia et al., 2020). In VAP patients, PA also has the highest associateddeath rates (65%) when compared to all other bacterial species (31%) (Chastre and
Fagon, 2002; Cotoia et al., 2020). PA is a multi-drug resistant organism, which is
normally innocuous in the environment, but can become highly opportunistic in
immunocompromised patients (Bassetti et al., 2018). In ventilated patients receiving
oxygen therapy, PA enters the lung usually by contact with contaminated surfaces on
endotracheal tubes, drainage cuffs, or by direct contact of healthcare workers (Cotoia
et al., 2020). Upon colonization of PA in the lung, the bacteria utilize a variety of
virulence factors that cause the breakdown of lipids, elastic fibers, and proteins,
activate quorum sensing, and elicit an inflammatory response (Hauser, 2011). As a
consequence, PA pneumonia can disrupt or destroy the alveolar-capillary barrier,
3

resulting in pulmonary edema, hypoxemia, and respiratory failure (Chastre and
Fagon, 2002; Cotoia et al., 2020; Hauser, 2011).
Currently, VAP patients with PA pneumonia are treated with cocktails of antibiotics
including aminoglycosides, cephalosporin, carbapenem, and other broad-spectrum
antibiotics (Bassetti et al., 2018; Cotoia et al., 2020). However, treatment with these
antibiotic cocktails for PA pneumonia in VAP has yielded unconvincing clinical results
of the efficacy of this therapeutic strategy (Cotoia et al., 2020). Thus, other therapies
that can target more efficient clearance of these pathogenic organisms is critically
needed. Since alveolar macrophages are a first line of defense in the airways against
invading pathogens like PA, impairment of macrophage functions cause the increased
the susceptibility to bacterial infections in animals and humans exposed to hyperoxia
(Baleeiro et al., 2003; Patel et al., 2013; Reddy et al., 2009; Sitapara et al., 2014).
Therefore, alveolar macrophages are a potential therapeutic target to improve
outcomes for individuals that are immunocompromised by hyperoxic oxygen
therapy.

1.2. Impact of Hyperoxia on Macrophage Function
The prolonged exposure of macrophages to hyperoxia induces the elevation of
intracellular reactive oxygen species (ROS) (Freeman et al., 1982). ROS produce a
phenomenon known as oxidative stress, a pathophysiological condition characterized
by the relative higher amount of oxidants to reductants and their correlation with
disease pathogenesis (Burton and Jauniaux, 2011). Free radicals derived from oxygen
and other ROS can be controlled through the containment of antioxidant defense
systems (Aerts et al., 1995; Birben et al., 2012; Cho et al., 2002; Gore et al., 2010). The
4

complex network of antioxidant molecules and enzymes in the cell are critical for
mitigating oxidative stress and maintain cellular homeostasis (Birben et al., 2012).
However, prolonged exposure to hyperoxia results in an overwhelming and
continuous production of ROS, which can surmount the endogenous antioxidant
defense system and induce mitochondrial damage (Freeman et al., 1982; O’Donovan
and Fernandes, 2000; Pagano and Barazzone-Argiroffo, 2003). Mitochondrial damage
by hyperoxic exposure is partly due to the generation of ROS, such as superoxide and
hydroxyl radicals (Goscin and Fridovich, 1973; Guo et al., 2013; Indo et al., 2015;
Majima et al., 1998; Morrow et al., 2007). Superoxide is generated by the one electron
reduction of molecular oxygen and has a half-life of approximately 1-4 µs (Gielis et al.,
2017). Superoxide is commonly generated as a reaction byproduct from cytochromes
and enzymes containing iron-cores, such as the complexes of the electron transport
chain (ETC) (Li et al., 2013). Upon the exposure to hyperoxia, intramitochondrial
levels of oxygen increase (Düssmann et al., 2017), which may augment the basal
mitochondrial superoxide byproduct formation. Importantly, hyperoxia exposure has
been shown to decrease the activities of complex I, II, and IV of the ETC, which results
in increased amounts of electron leakage, and the subsequent reduction of molecular
oxygen to superoxide anion (Resseguie et al., 2015). Superoxide can then be
converted to hydrogen peroxide in the mitochondria by manganese superoxide
dismutase (MnSOD or SOD2) and by copper-zinc SOD (CuZnSOD or SOD1) in the
cytosol (Wang et al., 2018). Hydrogen peroxide can then be either detoxified into
water by catalase or permeate out of the mitochondria and contribute to cytosolic
ROS and cause oxidative stress (Birben et al., 2012; Guo et al., 2013). Excessive
5

mitochondrial superoxide accumulation can cause oxidative damage to ETC enzymes
and affects the levels and localization of electron carriers (e.g. NADH, FADH2,
cytochrome C) that are involved in oxidative phosphorylation, resulting in impaired
energy production, changes in the mitochondrial membrane potential, and the
additional production of ROS (Bhatti et al., 2017; Guo et al., 2013; Zorova et al., 2018).
As a consequence, impaired energy production and excessive ROS has profound
impacts on the phagocytic function of macrophages (Okpala et al., 2015; O’Reilly et
al., 2003). Macrophage phagocytosis requires readily available pools of ATP
(Borregaard and Herlin, 1982), which is depleted due to the lack of functional
mitochondria under hyperoxic conditions (Monick et al., 2008).
In response to invading pulmonary pathogens, macrophages attempt to eradicate
these microbes through the activation of bactericidal enzymes like NADPH oxidase
(NOX2) (Griffith et al., 2009). NOX2 enzymes utilize oxygen as a substrate to generate
superoxide anion in the cytosol and in the phagolysosomes of phagocytosed
pathogens (Griffith et al., 2009; Parinandi et al., 2003). In pulmonary epithelial and
endothelial cells, exposure to hyperoxia results in the increase of cytosolic superoxide
levels, which was found to be dependent on NOX2 and NOX4 activation (Parinandi et
al., 2003; Zhang et al., 2003). In hyperoxia-exposed NOX2 null mice, NOX4 activation
contributes to alveolar capillary barrier dysfunction, pulmonary edema, and
inflammatory lung injury (Griffith et al., 2009; Pendyala et al., 2009).
Thus, the combination of mitochondrial generated ROS that permeates into the
cytosol and also ROS generated in the cytosol contribute to total increase in the
hyperoxia-induced elevated cytosolic ROS levels in macrophages. As a consequence,
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high cytosolic ROS levels can cause the oxidation of proteins and lipids resulting in
the post-translational modification (PTM) of F-actin fibers (Morrow et al., 2007;
O’Reilly et al., 2003). F-actin is a critical cytoskeletal component that is used by
macrophages to migrate to and form phagosomes around opsonized pathogens like
PA (Hartwig and Yin, 1988). As a result, hyperoxia-induced F-actin oxidation
contributes to the formation of stress fiber filaments, the dysregulation of actin
polymerization, and impairs the migratory and phagocytosis functions of
macrophages (Morrow et al., 2007; O’Reilly et al., 2003). The impaired phagocytic
functions of hyperoxia-induced oxidative stress in macrophages can be attenuated by
treatment with activators of antioxidant defense pathways like sulforaphane or with
supplemental antioxidants such as ascorbic acid, n-acetyl cysteine, and exogenous
superoxide dismutase (SOD) (Morrow et al., 2007; Patel et al., 2020). Importantly,
antioxidant treatment protects against oxidation of F-actin filaments and restores the
antibacterial and phagocytic functions of macrophages (Arita et al., 2007; Morrow et
al., 2007; O’Reilly et al., 2003). Thus, the prolonged exposure to hyperoxia has
profound deleterious effects on macrophage functions to migrate, phagocytose, and
kill invading pathogens, which can be protected against by treatment with
supplemental and activators of antioxidant pathways.

1.3. The Vagus Nerve Mediated Cholinergic Anti-Inflammatory Pathway
Alveolar macrophages perform their host defense functions, which are mediated in
part by both autocrine and paracrine-like signaling of cytokines and chemokines.
Indeed, the balance between pro- and anti-inflammatory cytokine and chemokine
production has been previously identified as a neuromodulator mechanism known as
7

the cholinergic anti-inflammatory pathway (Borovikova et al., 2000). The cholinergic
anti-inflammatory pathway is mediated by the vagus nerve, which is the 10th cranial
nerve (Tracey, 2002). In response to damage, pathogens, or inflammatory signals, the
afferent vagus nerve conduct signals to the central nervous system where they are
integrated and relayed to effector organs via the efferent vagus nerve. Acetylcholine
is released from the efferent vagus nerve innervating pulmonary neuroendocrine
cells and can bind to macrophage α7 nicotinic acetylcholine receptors (α7nAChRs)
and downregulate hyper-inflammatory responses, such as those during VAP (Pavlov
et al., 2003). In addition, cholinergic anti-inflammatory pathway-mediated signaling
has been identified as a missing link that plays a role in controlling autophagy and
regulating cellular metabolic homeostasis (Chang et al., 2019; Lu et al., 2014).

1.4. α7nAChR as a Pharmacological Target for Attenuating HyperoxiaCompromised Macrophage Functions
Previously, we and others have shown that the hyperoxia-compromised innate
immune functions of alveolar macrophages are significantly attenuated by
pharmacological activators of the α7 nicotinic acetylcholine receptors (α7nAChRs)
(Ulloa, 2005; Wang et al., 2004). The α7nAChR is a homomeric pentamer and a
ligand-gated ion channel found on both neuronal and non-neuronal cells (Báez-Pagán
et al., 2015; Bagdas et al., 2016; Papke et al., 2018). Upon stimulation with
endogenous acetylcholine, choline or other agonists, there is a rapid influx of calcium
ions into neurons that activate certain calcium-dependent pathways (Báez-Pagán et
al., 2015; Hoover, 2017). Evidence suggests that the activation of non-neuronal cells,
such as macrophages, produces an influx of calcium ions but does not significantly
change whole cell currents (Skok, 2009; Villiger et al., 2002). A number of studies
8

have shown that the activation of peripheral α7nAChR produces anti-inflammatory
effects (de Jonge et al., 2005; Papke et al., 2018; Wang et al., 2003). It has been
postulated that the anti-inflammatory effect produced by the activation of α7nAChR
on peripheral immune cells such as macrophages may be due to: 1) inhibition of the
phosphorylation of the transcription factor STAT3, which subsequently decreases the
activation of certain genes that produce inflammatory cytokines (Báez-Pagán et al.,
2015); 2) activation of the PI3K/Akt/Nrf2 antioxidant pathway and induction of
heme oxygenase-1 (HO-1) and 3) the inhibition of NF-kB p65 subunit
phosphorylation and subsequent nuclear-translocation through STAT3-NF-kB
convergence (Báez-Pagán et al., 2015; Hoover, 2017).
Previously, our lab has shown that administration of GTS-21, a partial agonist of the
α7nAChR, significantly increased bacterial clearance and decreased lung injury in
hyperoxia-exposed mice with PA pneumonia (Sitapara et al., 2014). Importantly, GTS21 activates the cholinergic anti-inflammatory pathway, which in turn has been
shown to attenuate the phagocytic function of macrophages compromised by the
prolonged exposure to hyperoxia (Sitapara et al., 2014). However, other clinically
relevant endpoints, such as mortality rates, were not significantly affected by GTS-21
administration (unpublished results). Moreover, treatment with α7nAChR agonists
like acetylcholine, attenuates mitochondrial perturbation in LPS-primed mouse
primary macrophages (Lu et al., 2014). Yet, it remains unclear if macrophage innate
immune functions can be improved by attenuating mitochondrial dysfunction.
Consequently, we wanted to ascertain the efficacy of a next generation α7nAChR
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activator in animals and in an in vitro model, where macrophage functions are
compromised by hyperoxia exposure.

1.5. GAT107 and Agonistic Positive-Allosteric Modulators
In this study, we determined the efficacy of the (+) - enantiomer of racemic 4-(4bromophenyl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinoline-8-sulfonamide,
GAT107, to attenuate hyperoxia-induced impairment of host innate immune
functions and its underlying mechanisms. GAT107 is positive allosteric modulator
(PAM) and direct allosteric activator (DAA) that 1) augments or potentiates the
response to orthosteric site ligands and 2) activates the α7nAChR ion channel (in the
absence of an orthosteric agonist) by binding to an allosteric site distinct from that of
the PAM site (Bagdas et al., 2016; Horenstein et al., 2016; Papke et al., 2018, 2014;
Thakur et al., 2013). In vitro, the α7nAChR can be rapidly desensitized by
acetylcholine (ACh). Interestingly, the coadministration of GAT107 with ACh
produces a significant decrease in the ACh-induced desensitization (Horenstein et al.,
2016, 2016; Papke et al., 2014). It is likely that GAT107 facilitates the conversion of
desensitized states to conducting states which surmounts receptor desensitization
(Horenstein et al., 2016, 2016; Papke et al., 2014).
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1.6. Hypothesis
GAT107 improves the survival of hyperoxia-compromised mice challenged with
Pseudomonas aeruginosa (PA) lung infection via enhancing host defense functions of
macrophages.
Aim 1: To determine if GAT107 improves survival in mice exposed to hyperoxia and
challenged with PA lung infection.
Aim 2: To determine if GAT107 attenuates hyperoxia-compromised host defense of
PA bacterial clearance in the lungs of mice.
Aim 3: To determine if GAT107 attenuates hyperoxia-induced phagocytic dysfunction
modulating redox imbalance in macrophages.
Aim 4: To determine if GAT107 can ameliorate hyperoxia-induced mitochondrial
redox imbalance and dysfunction.
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2. MATERIALS AND METHODS
2.1. Cell Culture and Special Reagents
Murine macrophage–like RAW 264.7 cells (TIB-71; American Type Culture Collection
(ATCC), Manassas, VA) were cultured in Dulbecco's Modified Eagle Medium (DMEM)
and supplemented with 10% FBS (Atlanta Biologicals, Lawrenceville, GA). Cells were
maintained at 37˚C in normoxia (5% CO2/21% O2) for 24 h, allowed to grow to 70–
80% confluency and subcultured every 2 days. Bone marrow was harvested from 68-week-old male C57BL/6 mice (Jackson laboratories), isolated, and cultured to allow
for differentiation into bone marrow-derived macrophages (BMDM), as previously
described (Weischenfeldt and Porse, 2008). Hyperoxic exposure was performed in
sealed, humidified chambers (Billups-Rothenberg Inc., Del Mar, CA) flushed with 95%
O2/5% CO2 at 37˚C. An oxygen analyzer (MSA Medical Products, Pittsburgh, PA) was
used to monitor the O2 levels.

2.2. Animal Studies
Male C57BL/6 mice (6 to 10 weeks old; The Jackson Laboratory, Bar Harbor, ME, USA)
were used in this investigation based on a protocol (protocol #1953) approved by the
Institutional Animal Care and Use Committees of St. John’s University. The mice were
housed in a specific pathogen-free environment, maintained at 22°C in ≈50% relative
humidity and with a 12 h light/dark cycle. All mice had ad libitum access to standard
rodent food and water. Mice were randomized to receive either 3.3 mg/kg of ((+) (4-(4-bromophenyl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinoline-8sulfonamide, GAT107, donated by Dr. Ganesh S. Thakur, Northeastern University,
Boston, MA, or saline, administered by intraperitoneal injection at 24, 36, and 48 h
12

after the onset of hyperoxic exposure. After 48 h of exposure, the mice were
inoculated with 0.1 × 108 colony-forming units (CFUs) of Pseudomonas aeruginosa
(PA) by making a 1- to 2-cm incision on the neck to expose the trachea after
anesthetization with sodium pentobarbital (75 mg/kg). PA was used as the selected
pathogen as it is associated with 21% of all VAP cases (Richards et al., 1999). Twenty
four hours after bacterial inoculation, mice were euthanized via exsanguination and
bronchoalveolar lavage (BAL) and lung tissues were immediately collected as
described previously (Patel et al., 2013). For the collection of BAL, the lungs were
lavaged with PBS, and afterwards, the lungs were excised and immediately placed
into 1 mL cold PBS containing a protease and phosphatase inhibitors cocktail (Pierce
Thermo Scientific) followed by homogenization by a Dounce tissue homogenizer.
For animal survival studies, mice were subjected for 72 h of hyperoxia exposure and
inoculated similarly as stated above. Mice were then monitored every hour over the
course of 24 h for survival.

2.3. Exposure to Hyperoxia
Male C57BL/6 mice and cultured macrophages were exposed to hyperoxia as
previously described (Patel et al., 2013). Briefly, animals were placed in microisolator
cages (Allentown Caging Equipment, Allen-town, NJ, USA), which were kept in a
Plexiglas chamber (BioSpherix, Lacona, NY, USA) and exposed to ≥95% O2 for up to
48 h. The exposure of murine macrophage RAW 264.7 cells was conducted in
humidified Plexiglas chambers (Billups-Rothenberg, Del Mar, CA, USA), flushed with
95% O2/5% CO2 at 37°C for 24 h. An oxygen analyzer (MSA; Ohio Medical
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Corporation, Gurnee, IL, USA) was used to monitor the O 2 concentration in the
chamber.

2.4. Bronchoalveolar Lavage and Protein Quantification
Murine bronchoalveolar lavage (BAL) fluid was obtained as described previously
(Patel et al., 2013). Briefly, mice were anesthetized by an intraperitoneal injection of
sodium pentobarbital (75 mg/kg). After a 1- to 2-cm incision was made on the neck,
the trachea was dissected, and a 20-gauge × 1.25-inch intravenous catheter was
inserted caudally into the lumen of the exposed trachea. The lungs were gently
lavaged twice with 1 mL sterile, nonpyrogenic phosphate-buffered saline (PBS)
solution (Mediatech, Herndon, VA, USA) containing a cocktail of protease and
phosphatase inhibitors (Thermo Pierce Scientific). BAL samples were centrifuged at
200 x g at 4˚C for 5 minutes, and the resultant supernatants were stored flash frozen
in liquid nitrogen and then stored in a freezer at −80°C. Total protein content in BAL
was determined by using the Pierce Bicinchoninic acid (BCA) assay Kit (Thermo
Fisher, Waltham, MA) as per the manufacturer’s instructions.

2.5. Quantitative Bacteriology
Lung homogenate and BAL were serially diluted, and the viable bacterial counts were
determined using a colony formation unit (CFU) assay by plating onto Pseudomonas
Isolation Agar (Difco, Sparks, MD), and incubating at 37˚C for 18 h.

2.6. Assay for Oxidative Stress and Antioxidant Potential
Oxidative stress was determined by measuring the oxidation–reduction potential
(ORP) using the RedoxSYS Diagnostic System (Luoxis Diagnostics, Inc., Englewood,
CO). Lung homogenate was evaluated for its oxidative-reduction potential (ORP)
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reported in millivolts (mV) and the capacity of the ORP (cORP) also known as the
antioxidant potential measured in µcoloumbs (µC) at room temperature, using the
protocol provided by the manufacturer.

2.7. Measurement of SOD1 Activity
RAW 264.7 cells were seeded in 6-well plates, exposed to hyperoxia, and treated as
with GAT107 (3.3 µM) for 24h. After 24h, cells were washed 3x in PBS and lysed with
cell lysis buffer (Cell Signaling Technology, Danvers, MA) that contained Halt protease
and phosphatase inhibitor cocktail (Thermo Fischer, Waltham, MA). The total protein
content of cell lysate was determined by using the Pierce Bicinchoninic acid (BCA)
assay Kit (Thermo Fisher, Waltham, MA) as per the manufacturer instructions. Equal
amounts of total protein from non-denatured samples were loaded onto 12% nativePAGE and separated at 100V at 4˚C for 90 minutes. Native-PAGE gels were then
washed with 3x distilled water and then incubated with 2.43 mM nitrotetrazolium
blue (Acros Chemical), 2.85 µM riboflavin (Sigma), and 28 mM TEMED (GE
Healthcare) for 20 minutes, protected from light, and at room temperature, as
described (Beauchamp and Fridovich, 1971). After 20 minutes, gels were placed on a
light box and allowed to develop. The presence of achromatic bands represents the
inhibition of the reduction of nitro tetrazolium blue by the SOD1 enzymatic and was
detected by Bio-Rad ChemiDoc.

2.8. 2’,7’-Dichlorofluorescin diacetate (DCFH-DA) reactive oxygen species
(ROS) detection assay
RAW 264.7 cells were seeded in quadruplicate in 96-well black wall, clear bottom
plates, exposed to hyperoxia, and treated as previously described. After 24 h, cells
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were analyzed using the DCFH-DA assay (Cell Biolabs, San Diego, CA), according to
manufacturer instructions. In brief, cells were incubated with 1 mM DCFH-DA for 30
minutes at 37˚C, then washed three times with warm PBS. The presence of total
intracellular DCF (an indicator for ROS levels) was determined by lysing cells, as
described previously (Patel 2020), and measuring a green fluorescent signal at
480/530nm, using a Biotek Synergy LX multimode reader (Winooski, Vermont, USA).
DCF relative fluorescent units were then reported as a percent relative to the 21% O 2
exposure group (normoxic or control group).

2.9. Phagocytosis Assay and Assessment of Actin Stress Filament
Formation
The phagocytosis assay was performed as previously described, with minor
modifications (Morrow et al., 2007; Sitapara et al., 2014). Briefly, RAW 264.7 cells or
BMDMs were seeded in 24-well plates and allowed to adhere for 6 h followed by
exposure to 95% O2 in the absence or presence of GAT107 (3.3 µM) for 24 h. RAW
264.7 cells were incubated at 37 ˚C for 1 h with opsonized FITC-labeled latex beads
(Polysciences, Warrington, PA) at a ratio of 100 : 1 (beads : cell). Macrophages were
incubated with 0.04% Trypan blue in PBS for 10 minutes to quench the beads that
were not internalized by the macrophages. To visualize the uptake of FITC-labeled
latex beads, macrophages were fixed with 4% paraformaldehyde for 10 minutes,
washed with PBS, and stained with 4′,6-diamidino-2-phenylindole (DAPI, Molecular
Probes, Eugene, OR). To visualize the cell cytoskeleton, cells were stained with
rhodamine phalladoin (Molecular Probes, Eugene, OR). The phagocytosis or uptake
of the beads was assessed visually using an Evos Fluorescent Microscope (Thermo
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Fischer, Waltham, MA) followed by counting 200 individual macrophages per well in
duplicates from three independent experiments by a blinded person for each
experimental group. To assess the hyperoxia-induced modification of actin
polymerization, a modified experiment method was used (O’Reilly et al., 2003). Using
the fluorescent micrographs obtained from the above phagocytosis assay, a Fiji
ImageJ analysis (version 2.0) with the JACoP plugin was used to determine a Mander’s
Correlation Coefficient using thresholds for the amount of phalladoin signal
associated with the DAPI signal. This value was converted to percentage to estimate
the amount of polymerized F-actin and stress filament formation.

2.10. Protein Carbonyl Formation
The amount of total protein oxidation and carbonyl formation was determined by
using a commercially available Oxidized Protein Western Blot Kit (Abcam,
Cambridge, UK) based on the manufacturer instructions. Equal amounts of whole cell
lysate from three to four independent experiments were subjected to a protein
carbonyl derivatization with 2,4-dinitrophenylhydrazone (DNP-hydrazone) in the
presence of DNP-hydrazine or left unreacted as a negative control. The samples were
separated by 12% SDS-PAGE and transferred to PVDF membranes. The membranes
were washed and blocked in 5% milk/TBST solution. Next, membranes were washed
and incubated with secondary anti-DNP antibody, washed, and the immunoreactive
DNP bands were detected using enhanced chemiluminescence (ECL) reagents (Pierce
Thermo Scientific) by a Bio-Rad ChemiDoc XRS+ system (Biorad, Hercules, CA).
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2.11. Western Blot Analysis
For intracellular protein analysis, cells were washed 3x in PBS and lysed with cell lysis
buffer (Cell Signaling Technology, Danvers, MA) that contained Halt protease and
phosphatase inhibitor cocktail (Thermo Fischer, Waltham, MA). The total protein
content of cell lysate was determined by using the Pierce Bicinchoninic acid (BCA)
assay Kit (Thermo Fisher, Waltham, MA) as per the manufacturer instructions.
Samples were loaded onto 12% or 15% SDS–polyacrylamide gels (Bio-Rad, Hercules,
CA) and transferred to Immobilon-P membranes (Millipore, Bedford, MA).
Nonspecific binding sites on the membrane were blocked by incubating the
membrane with either 5% nonfat dry milk (Bio-Rad, Hercules, CA) in Tris- buffered
saline (TBS) containing 0.1% Tween 20 (TBST) for 1h at room temperature.
Subsequently, membranes were washed three times with TBST and incubated
overnight at 4˚C with anti-HO-1 (1:1000, #ab13248, Abcam, Cambridge, UK), antiMnSOD (1:1000, #AD-SOD-110, Enzo, New York, NY), and anti-pan-actin (1:1000,
#8456, Cell Signaling) antibodies diluted in 5% nonfat dry milk in TBST. After three
washes with TBST, the membranes were incubated with goat anti-rabbit horseradish
peroxidase–coupled secondary antibody (1:5,000; GE Healthcare, Chicago, IL) for 1 h
at room temperature. Subsequently, membranes were washed three times again with
TBST and the immunoreactive proteins were visualized using the SuperSignal West
Pico Plus Chemiluminescent Substrate (Thermo Fisher, Waltham, MA) per the
manufacturer instructions. The images were developed using Bio-Rad ChemiDoc XRS
(Bio-Rad, Hercules, CA). Immunoreactive bands were quantified using ImageJ
software (version 2.0.0).
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2.12. Nrf2 Analysis
Nrf2 activation was determined by determining the amount of immunofluorescent
Nrf2 nuclear colocalization. RAW 264.7 cells were seeded and treated as described in
the DCFH-DA experiment. After 24h, cells were permeabilized 0.1% Triton X-100
(Millipore Sigma, St. Louis, MO) made in PBS, blocked 10% goat serum (Millipore
Sigma) in PBS, and incubated with anti-Nrf2-antibody (donated by Dr. Ed Schmidt of
Montana State University) overnight. Cells were washed and immunoreacted with
AlexaFluor488 (Pierce Thermo Scientific). Fluorescent micrographs were captured
using an Evos fluorescent microscope. The images were analyzed for the amount of
Nrf2 localized in the nucleus using a Mander’s Correlation Coefficient with thresholds
as described above in the actin stress filament formation (see Section 2.9). The
amount of Nrf2 signal located within the same signal as the nucleus was used as a
marker of Nrf2 activation. The Mander’s correlation coefficient were then reported
as a percent of total Nrf2 signal within the nucleus.

2.14. Measurement of Mitochondrial
Mitochondrial Superoxide

Membrane

Potential

and

RAW 264.7 cells were seeded in 96-well black wall, clear bottom plates, exposed to
hyperoxia, and incubated with and without GAT107 (3.3 µM) as previously described.
Macrophage mitochondrial membrane potential was determined by using the
tetramethylrhodamine ethyl ester (TMRE) Mitochondrial Membrane Potential Assay
Kit (Abcam, Cambridge, UK) as per the manufacturer’s instructions. In brief, after the
24 h incubation period, cells were incubated with 1 µM of TMRE for 20 minutes at
37˚C. Prior to TMRE, a negative control group for mitochondrial membrane
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polarization was generated by incubating the cells with 20 µM of the carbonyl cyanide
4-(trifluoromethoxy)phenylhydrazone (FCCP) uncoupling reagent for 15 minutes at
37˚C. After incubation with TMRE, cells were gently washed with PBS containing 0.2%
BSA and fluorescence detected at 549nm/570nm using a Synergy LX multimode
reader. In another set of experiments, macrophages were cultured and treated as
described for the TMRE assay and then incubated with MitoTracker Green FM
(Thermo Fisher, Waltham, MA) to determine the mitochondrial density as per the
manufacturer’s instructions. MitoTracker Green FM accumulates in mitochondria,
independent of the membrane potential, and serves as a marker for total
mitochondrial density. The relative fluorescent levels of MitoTracker Green FM in
each condition group were then normalized to the 21% O 2 control group, and these
values were used to normalize the percent TMRE relative fluorescence values, which
was represented as a bar graph as the percent TMRE / MitoTracker Green to
demonstrate the mitochondrial membrane polarization status. For the measurement
of mitochondrial superoxide levels, after 24h of incubation, macrophages were
incubated with 5 µM of the MitoSOX reagent (Invitrogen, Carlsbad, CA) for 10 minutes
at 37˚C and washed three times with 37˚C PBS as per the manufacturer’s instructions.
The presence of mitochondrial superoxide was detected using a Synergy LX
multimode reader at the settings of 510 / 580 nm.

2.15. Measurement of MnSOD Activity
After 24 h of hyperoxic exposure and incubation with GAT107 (3.3µM), RAW 264.7
macrophage cell lysates were prepared as described above (Section 2.11). Equal
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amounts of protein were tested for the enzymatic activity of MnSOD using a
Superoxide Dismutase (SOD) Colormetric Activity Kit (Thermo Fisher) as per
manufacturer’s instructions. In brief, non-mitochondrial iron SOD (FeSOD) and
copper zinc SOD (CuZnSOD) were inhibited by incubating the cell lysate with cyanide.
Cell lysates containing cyanide were then incubated with a xanthine oxidase reagent
that generates superoxide in the presence of oxygen. The amount of superoxide not
dismutated into hydrogen peroxide by MnSOD is then reacted with a nitro blue
tetrazolium blue reagent to yield a yellow color. This chromogenic reaction product
was read at 450 nm on a Synergy LX multimode reader (Biotek, Winooski, VT). The
results were compared to a standard curve generated by using bovine erythrocyte
SOD (produced without the addition of cyanide) and normalized to total protein
concentrations.

2.16. Immunoprecipitation and Immunodetection
RAW 264.7 cells were exposed to 24h of hyperoxia and incubated with GAT107 (0 or
3.3 µM) as described above. Cell lysates were collected, and protein content
determined as described for the Western blot analysis (section 2.11). MnSOD was coimmunoprecipitated from cell lysates using the Pierce Direct Magnetic IP/CoImmunoprecipitation Kit (Thermo Scientific, Waltham, MA) using a polyclonal antiMnSOD antibody (Enzo, New York, NY) per the manufacturer’s instructions. After
immunoprecipitation, samples were immediately subjected to SDS-PAGE and
Western blot analysis as described above (section 2.11). Western blot analysis was

21

conducted as described above using anti-MnSOD antibody (1:1000, Enzo, New York,
NY) and monoclonal anti-glutathione antibody (1:1000, Virogen, Watertown, MA).

2.17. Statistical Analysis
The statistical analyses were carried out using GraphPad Prism statistical software
(version 7.0a). The results are presented as the mean ± SEM. The data were analyzed
for statistical significance according to analysis of variance (ANOVA) with Dunnett’s
post hoc analysis. Animal survival data was analyzed by using a Kaplan-Meier curve.
Glutathionylation versus MnSOD activity data was analyzed using a correlation
analysis using a two-tail Pearson Correlation Coefficient test. A 95% confidence
interval was used and a p-value less than 0.05 was considered significant.
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3. FIGURES AND FIGURE LEGENDS
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Figure 1. Systemic administration of GAT107 increases survival in mice with
exposed to hyperoxia and challenged with PA lung infection
Male C57BL/6 were exposed to >95% O2 for 72 h and then inoculated with PA (0.1 x 108
CFUs / mouse) and then returned to 21% O2 after inoculation. Mice were randomized to
receive GAT107 (0 or 3.3 mg/kg) administered via intraperitoneal injection every 12 h
starting at hour 24 of hyperoxia. After mice were inoculated, animal survival was
monitored and recorded every hour for 24 h and represented above as a Kaplan-Meier
curve. Data were analyzed using the log-rank Mantel-Cox test; *p < 0.05 compared to
hyperoxia exposed vehicle treated control group (n = 5 - 10 mice / group).

23

****

log CFU / mL in BAL

10

****

B

8
6
4
2
0

GAT107
DMSO Vehicle
O2 (%)

****

10

log CFU / mL in Lung

A

****

8
6
4
2
0

21

+
95

GAT107
DMSO Vehicle
O2 (%)

+
+
95

21

+
95

+
+
95

Figure 2. Systemic administration of GAT107 improves bacterial clearance in mice
exposed to 48 h hyperoxia and challenged with PA infection.
Male C57BL/6 were exposed to >95% O2 (hyperoxia) for 48 h and then inoculated with
PA (0.1 x 108 CFUs / mouse) and then returned to 21% O2 after inoculation. Mice were
randomized to receive GAT107 (0 or 3.3 mg/kg) administered via intraperitoneal
injection every 12 h starting at hour 24 of hyperoxia. BAL and lung tissue were harvested
24 h after inoculation. Viable bacteria in the airways and lungs were quantified by plating
serials dilutions of (A) BAL and (B) lung homogenate and expressed as the log of colony
forming units (CFUs) per mL. Data represent the mean ± SEM from n = 6-7 mice per
group. Statistical differences were determined between all groups and indicated a **** p
< 0.0001 compared to the hyperoxia exposed vehicle control group.
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Figure 3. GAT107 restores hyperoxia-compromised macrophage phagocytic
function in a macrophage cell line and in primary macrophages.
RAW 264.7 were either exposed to 21% O2 (white bar) or 95% O2 (hyperoxia) (black bar)
with or without GAT107 (grey bars). Cells were incubated with FITC-labeled minibeads
for 1 h and stained to visualize the cytoskeleton and nucleus. Immunofluorescent
micrographs show the phagocytosed beads (green), cytoskeleton (red), and nucleus
(blue) of (A) RAW 264.7 cells and (B) BMDMs. The bar graphs represent the
quantification of phagocytosis of at least 200 cells was represented as a percent beads
phagocytosed. Quantification of phagocytosis for (C) RAW 264.7 and (D) BMDMs cells.
Each value represents the mean ± SEM of three independent experiments for each group.
Statistical differences were determined between all groups and indicated a **** p <
0.0001, *** p < 0.001 compared to the hyperoxia exposed vehicle control group.
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Figure 4. GAT107 Mitigates Hyperoxia-Induced Actin Oxidation and Alterations in
Polymerization.
RAW 264.7 were either exposed to 21% O2 or 95% O2 (hyperoxia) with or without
GAT107. After 24 h, (A) the actin polymerization was analyzed using fluorescent
micrographs obtained as described in the Phagocytosis Assay in the methods, and the
ratio of actin to the nuclei were reported as a percent of non-overlapping signals obtained
from ImageJ’s co-localization analysis plugin and computation of the Manders’
Correlation Coefficient. Each value represents mean ± SEM of three independent
experiments for each group. Statistical differences were determined between all groups
and indicated a **** p < 0.0001, ** p < 0.01 compared to the hyperoxia exposed vehicle
control group. (B) Macrophages were then also analyzed for total protein carbonylation
by oxidized protein Western blot and the 43kD immunoreactive band was used to
evaluate the extent of actin oxidation (as indicated by the arrow) for 3 – 4 independent
experiments per group.
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Figure 5. Systemic administration of GAT107 attenuates oxidative stress via
enhancement of total lung antioxidant potential.
Male C57BL/6 mice were exposed to 95% O2 (hyperoxia) for 48 h and then inoculated
with PA (0.1 x 108 CFUs / mouse), and then returned to 21% O2 after inoculation. Mice
were randomized to receive GAT107 (0 or 3.3 mg/kg) administered via intraperitoneal
injection every 12 h starting at hour 24 of hyperoxia. Lung tissue was harvested 24 h after
inoculation. Lung homogenate was analyzed for (A) oxidative-reduction potential (ORP)
measured in millivolts (mV) and (B) capacity of the ORP or total antioxidant potential
(cORP) measured in µCoulombs (µC) by the RedoxSys System. Data represent the mean
± SEM of two-independent experiments from n = 4 mice per group. Statistical differences
were determined between all groups and indicated a *p < 0.05 compared to the hyperoxia
exposed vehicle control group.
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Figure 6. GAT107 Attenuates Hyperoxia-Induced Oxidative Stress by Restoring
Hyperoxia-Compromised SOD1 Function.
RAW 264.7 were either exposed to 21% O2 (room air) (white bar) or 95% O2 (hyperoxia)
(black bar) with or without GAT107 (grey bars). After 24 h, (A) macrophages were
subjected to DCFH-DA Assay and the amount of fluorescent DCF signal within
macrophages was determined spectrophotometrically and reported as a percent relative
to the room air control to evaluate oxidative stress. (B) SOD1 activity was determined by
gel-based nitro tetrazolium blue gel assay as described in the methods section and (C)
reported as a fold change compared to the room air control group. Each value represents
mean ± SEM of three independent experiments for each group. Statistical differences
were determined between all groups and indicated a **** p < 0.0001, *** p < 0.001, ** p
< 0.01 compared to the hyperoxia exposed vehicle control group.
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Figure 7. GAT107 Activates the Nrf2/HO-1 Antioxidant Pathway.
RAW 264.7 were either exposed to 21% O2 (white bar) or 95% O2 (hyperoxia) (black bar)
with or without GAT107 (grey bars).After 24h, macrophages were fixed, permeabilized,
blocked, and incubated with a polyclonal anti-Nrf2-antibody overnight, then conjugated
to AlexaFluor 488, and then counterstained with DAPI to visualize the nucleus. (A)
Immunofluorescent micrographs were subjected to ImageJ co-localization analysis and
pseudo colored to determine the amount of Nrf2 signal (red) localized to the nucleus
(green) using the Manders’ Correlation Coefficient. (B) The bar graphs represent the
percent amount of total Nrf2 signal localized to the nuclear region. Under the same
experimental conditions, macrophages were also analyzed for levels of heme oxygenase1 (HO-1) and actin in whole cell lysate by Western blot analysis. (C) The representative
immunoreactive bands for HO-1 and actin and (D) the quantification of immunoreactive
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bands normalized to actin. Each value represents the mean ± SEM of two to three
independent experiments for each group. Statistical differences were determined
between all groups and indicated a **** p < 0.0001, * p < 0.05 compared to the hyperoxia
exposed vehicle control group.
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Figure 8. GAT107 restores hyperoxia-compromised macrophage mitochondrial
integrity and mitochondrial oxidative stress.
RAW 264.7 were either exposed to 21% O2 (white bar) or 95% O2 (hyperoxia) (black bar)
with or without GAT107 (grey bars). After 24 h, (A) macrophage mitochondrial integrity
was measured by tetramethylrhodamine, ethyl ester (TMRE) mitochondrial membrane
potential assay and normalized to MitoTracker Green. TMRE accumulates in
mitochondrial directly proportional to the mitochondrial membrane potential, while
MitoTracker Green localizes to mitochondria based on mitochondrial mass, not the
polarization status. (B) Macrophages were then analyzed for mitochondrial superoxide
using the MitoSOX dye after hyperoxia exposure. Each value represents mean ± SEM of
three independent experiments for each group. Statistical differences were determined
between all groups and indicated a **** p < 0.0001, ** p < 0.01 compared to the
hyperoxia exposed vehicle treated control group.
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Figure 9. GAT107 attenuates hyperoxia-compromised MnSOD activity.
RAW 264.7 were either exposed to 21% O2 (room air) (white bar) or 95% O2 (hyperoxia)
(black bar) with or without GAT107 (grey bars). After 24 h, whole cell lysates were
analyzed for total MnSOD levels by Western blot for MnSOD. (A) Representative Western
blots for MnSOD and actin and (B) the densiometric analysis of Western blot bands. (C)
RAW 264.7 cell lysate was used to determine MnSOD activity using a SOD activity kit in
the presence of cyanide to inhibit non-MnSOD activities. Each value represents mean ±
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SEM of three independent experiments for each group. #p < 0.05, versus the room air
control group; Statistical differences were determined between all groups and indicated
a **** p < 0.0001, *** p < 0.001 compared to the hyperoxia exposed vehicle treated
control group.
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Figure 10. The hyperoxia-induced glutathionylation of MnSOD is significantly
decreased by GAT107.
RAW 264.7 were either exposed to 21% O2 (white bar) or 95% O2 (hyperoxia) (black bar)
with or without GAT107 (grey bars). After 24 h, whole cell lysates were coimmunoprecipitated

for

MnSOD.

(A)

Representative

Western

blots

for

immunoprecipitated MnSOD and conjugated GSH. (B) Densiometric analysis for
immunoreactive GSH and MnSOD bands were determined and the ratio of GSH to MnSOD
was reported as a percentage on the bar graph. Each value represents the mean ± SEM of
3-4 independent experiments for each group. Statistical differences were determined
between all groups and indicated a **** p < 0.0001, ** p < 0.01 compared to hyperoxia
exposed vehicle control group. (C) MnSOD activity was then compared to their samples
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respective corresponding percentage of MnSOD glutathionylation and presented as a
correlation plot. Each value on the correlation plot represents individual sample data
points from 3 – 4 independent experiments. The measure of strength between the X and
Y variables was determined by a two-tailed Pearson-correlation coefficient, which
computed a p < 0.0001 between MnSOD activity and percentage of MnSOD
glutathionylation.
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Figure 11. Proposed pathway of the efficacy of GAT107 on macrophages to alleviate
the bacterial burden in hyperoxia-compromised mice with PA lung infection.
The prolonged exposure to hyperoxia (O2) induces the accumulation of reactive oxygen
species (ROS) in the cytosol and mitochondria of macrophages. Macrophage
mitochondrial normally generate superoxide (O2-) as a byproduct of the electron
transport chain, which is rapidly dismutated by manganese superoxide dismutase
(MnSOD) into hydrogen peroxide (H2O2). However, under hyperoxic conditions, high
concentrations of oxygen contribute to both mitochondria dysfunction and
mitochondrial superoxide accumulation. Sustained high levels of superoxide
compromise MnSOD activity via promoting cysteine glutathionylation, which contributes
to increasing the total level of mitochondrial superoxide. In addition, cytosolic
36

antioxidant defense systems (e.g. SOD1) are also suppressed during the prolonged
exposure to hyperoxia. High levels of ROS accumulate in the cytosol, which oxidize F-actin
filaments, resulting in impaired macrophage phagocytic functions. Together, both
mitochondrial dysfunction and F-actin oxidation contribute to the impaired bacterial
clearance functions of macrophages, resulting in the increased bacterial burden in the
airways of mice with PA lung infection and higher mortality rates. Treatment with
GAT107 to macrophages activates α7nAChR and results in the activation of the Nrf2.
GAT107-induced Nrf2 activation upregulates heme oxygenase-1 (HO-1). Upregulated
levels of HO-1 then contribute to alleviating the oxidative burden in the mitochondria
and the cytosol. GAT107 then mediates the reduction in mitochondrial superoxide
levels, reduced MnSOD cysteine glutathionylation, and ameliorates mitochondrial
dysfunction. Together with alleviating F-actin oxidation via enhancing the
antioxidant response (HO-1 and SOD1) and improved mitochondrial functions,
GAT107 attenuates hyperoxia-induced macrophage phagocytic dysfunction. As such,
GAT107 improves the bacterial clearance of PA lung infection and increases the rate
of survival in hyperoxia-compromised mice.
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4. RESULTS
4.1. Systemic administration of GAT107 increases survival in mice
exposed to hyperoxia and challenged with PA lung infection
The prolonged exposure to hyperoxia is the critical mediator for the increased rates
of mortality in patients with pulmonary infection (Chastre and Fagon, 2002; Rello,
2005; Spalding et al., 2017; M. Wang et al., 2019). To ascertain whether GAT107
administration to hyperoxia-compromised mice with Pseudomonas aeruginosa (PA)
lung infection could improve animal survival rates, mice were initially exposed to 72
h of 95% O2. During the 72 h of hyperoxia exposure, mice were administered
intraperitoneally with GAT107 3.3 mg/kg or vehicle control as described previously
above (section 2.2). As demonstrated in Figure 1, mice which remained in hyperoxic
conditions had significantly higher mortality rates (20% of mice survived, p < 0.05) 24 h
after challenge with bacterial lung infection when compared to mice that remained in
room air (21% O2) conditions (100% of mice survived). In mice administered with
GAT107 (3.3 mg/kg), subjected to hyperoxic conditions, and challenged with PA lung
infection, there was a significant improvement of mouse mortality rates (37.5% of mice
survived, p < 0.05) when compared to hyperoxia control group. In addition,
administration of GAT107 increased the mean survival time to 18.25 hours versus just
15.25 hours in the hyperoxia control group. Therefore, these data suggest that GAT107
improves animal survival of hyperoxia-compromised mice with PA lung infection.

4.2. Systemic administration of GAT107 improves bacterial clearance in
mice exposed to 48 h hyperoxia and challenged with PA infection.
The prolonged exposure to hyperoxia can compromise the ability of subjects to clear
bacterial lung infections (Patel et al., 2016, 2013; Sitapara et al., 2014). To determine if
38

GAT107 can restore the compromised clearance of bacteria in the lungs, we subjected
mice to hyperoxia exposure, administered intraperitoneally (i.p.) of GAT107 3.3 mg/kg
and instilled PA into lungs (i.e., bacterial challenge). As shown in Figure 2, mice that
received prolonged exposure to 95% O2 (i.e., hyperoxia) and were challenged with PAinduced lung infection (vehicle control group), had significantly higher levels of bacterial
colonies in their airways (7.81 ± 0.24 log CFUs/mL, p < 0.0001) and lung tissue
homogenate (7.68 ± 0.07 log CFUs/mL, p < 0.0001) compared to mice that remained
at 21% O2 (3.24 ± 0.15 log CFUs/mL in airways and 3.62 ± 0.35 log CFUs/mL in lung
tissue homogenate). The mice that received 3.3 mg/kg i.p. of GAT107 (3.93 ± 0.52
CFUs/mL in airways and 4.49 ± 0.54 log CFUs/mL in lung tissue homogenate) had
significantly lower levels of bacterial colonies in their airway fluids and lung tissue
homogenate compared to the vehicle control group (****p < 0.0001). GAT107
administration had no significance difference when compared to room air control
animals. These data indicate that GAT107 significantly decreases the lung bacterial
burden in a mouse model of VAP.

4.3. GAT107 restores hyperoxia-compromised macrophage phagocytic
function in a macrophage cell line and in primary macrophages
The decreased ability to clear bacterial lung infections in subjects compromised by
hyperoxia exposure, is in part mediated by the impaired innate immune functions of
macrophages. To determine whether GAT107 can restore hyperoxia-compromised
macrophage function, RAW 264.7 and primary bone marrow-derived macrophages
(BMDMs) were exposed to >95% O2 (hyperoxia) for 24h and incubated with either
3.3 µM GAT107 or vehicle control (DMSO). The phagocytotic function of RAW 264.7
cells exposed to hyperoxia was significantly decreased (66.1 ± 2.5%, p < 0.0001)
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compared to cells that remained at 21% O2 (100 ± 0%). Hyperoxia-compromised
phagocytosis was significantly attenuated by 3.3 µM GAT107 (86.3 ± 4.7%, p <
0.0001) compared to the vehicle control group (65.08 ± 2.53%) (Figure 3A and C).
Furthermore, these effects were also replicated in primary BMDMs, where after
exposure to 24h of hyperoxia, their phagocytic activity was significantly decreased
(33.2 ± 5.3%, p < 0.0001), compared to macrophages that remained at 21% O2 (100
± 0%). GAT107 significantly increased the phagocytotic activity of BMDMs exposed
to hyperoxia (105 ± 13.9%, p < 0.001) compared to the vehicle control group (35.39
± 3.9%) (Figure 3B and D). GAT107 incubation in hyperoxia-compromised
macrophages showed no statistically significant difference when compared to cells
that remain in room air control conditions. These results suggest that in vitro, GAT107
can attenuate the hyperoxic-induced decrease in macrophage phagocytic activity.

4.4. GAT107 Attenuates Hyperoxia-Induced Actin Oxidation and
Alterations in Polymerization.
Exposure to macrophages with hyperoxia can result in oxidative post-translational
modification to F-actin filaments that are critical for macrophage innate immune
functions (Morrow et al., 2007; O’Reilly et al., 2003). To determine if GAT107 can
attenuate hyperoxia-induced actin oxidation and altered actin polymerization, RAW
264.7 macrophages were exposed to 24 h of 95% O2 (hyperoxia) and incubated with 3.3
µM GAT107. The fluorescent microscopic analysis and quantification of F-actin stress
fiber formation, similar to previous studies (Morrow et al., 2007; O’Reilly et al., 2003),
indicated that macrophages exposed to hyperoxia had significantly higher amounts of
stress actin filament formation as indicated by an increased phalladoin/DAPI ratio (91.25
± 1.09%, p < 0.0001), compared to cells that remained at room air (81.05 ±
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1.07%)(Figure 4A). Furthermore, 3.3 µM GAT107 significantly decreased stress actin
formation produced by hyperoxia (83.45 ± 1.53%, p < 0.01), compared to the vehicle
control group (89.53 ± 1.34%). GAT107 incubation to hyperoxia-compromised
macrophages had no statistical difference when compared to cells that remained in
room air control conditions. Furthermore, macrophages exposed to hyperoxia had
increased total protein oxidation compared to the macrophages that remained in
room air, and this was decreased by incubation with 3.3 µM GAT107 (Figure 4B). The
proteins that migrated to approximately 43 kD were used as an indicator of actin
oxidation. Based on the 43 kD marker proteins, we observed the same protein
oxidation trend, suggesting that GAT107 also reduces the amount of hyperoxiainduced actin oxidation. Overall, these results indicate that GAT107 attenuates
hyperoxia-induced alterations in actin polymerization by reducing the oxidation of
total protein and actin.

4.5. The systemic administration of GAT107 attenuates hyperoxiainduced oxidative stress and increases the total lung antioxidant
potential
Previous studies have shown that hyperoxia-induced oxidative stress mediates the
decreased bacterial clearance functions of mice, which can be ameliorated when
subjects are administered antioxidants, like ascorbic acid (Patel et al., 2016; Sitapara
et al., 2020). To determine if GAT107 mitigates excessive lung oxidative stress in mice
exposed to 95% O2 (hyperoxia) and challenged with PA lung infection, the oxidative
redox potential (ORP) and the lung antioxidant potentials (cORP) were determined.
As shown in Figure 5, mice subjected to 95% O2 had significantly higher oxidativereduction potentials (298 ± 44.3 mV, p< 0.05) and lower antioxidant potentials (0.16
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± 0.05 µC, p < 0.05), compared to mice that remained at 21% O2 (204.26 ± 7.5 mV and
0.27 ± 0.03 µC, respectively). Indeed, the i.p. administration of 3.3 mg/kg GAT107
significantly attenuated the hyperoxia-induced increased lung oxidative-reduction
potential (162.36 ± 22.1 mV, p<0.05), and increased the total antioxidant potential
(0.47 ± 0.09 µC, p < 0.05), compared to the vehicle control group. GAT107 ameliorated
hyperoxia-induced increased lung homogenate ORP to a level that showed no
statistically significant difference when compared to animals that remained in room
air control conditions. These data indicate that GAT107 attenuates lung oxidative
stress by increasing the total antioxidant potential.

4.6. GAT107 Attenuates Hyperoxia-Induced Oxidative Stress by Restoring
Hyperoxia-Compromised SOD1 Function
The prolonged exposure to hyperoxia induces oxidative stress and compromises the
innate immune functions of macrophages, which can be attenuated by the treatment
with antioxidants, like ascorbic acid and superoxide dismutase (Arita et al., 2007;
Morrow et al., 2007; Patel et al., 2020). To determine if hyperoxia-induced oxidative
stress is attenuated by GAT107, RAW 264.7 cells were exposed >95% O2 (hyperoxia)
and incubated with 3.3 µM GAT107. The prolonged exposure to hyperoxia
significantly increased the total intracellular ROS levels (305.79 ± 20.21%, p <
0.0001), compared to macrophages that remained at 21% O2 (100 ± 0%) (Figure 6A).
GAT107 significantly decreased total intracellular ROS levels (231.05 ± 5.75%, p <
0.0001), compared to vehicle control (353.28 ± 27.81%) (Figure 6A). The prolonged
exposure to hyperoxia significantly compromises SOD1 activity (45.59 ± 8.71%, p <
0.001), compared to cells that remained at 21% O2 (100 ± 0%) when compared to
21% O2 (Figure 6B). Hyperoxia-compromised SOD1 activity was significantly
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restored in macrophages following treatment with 3.3 µM GAT107 (84.63 ± 10.75%,
p<0.01), compared to vehicle control (41.56 ± 7.31) (Figure 6B). These results
suggest that hyperoxia-induced oxidative stress is decreased by GAT107, in part, by
the restoring the hyperoxia-compromised antioxidant activity of SOD1.

4.7. GAT107 Activates the Nrf2/HO-1 Antioxidant Pathway
Previous studies indicate that the activation of Nrf2 can protect mice against
hyperoxia-induced acute lung injury and macrophage dysfunction by upregulating
enzymes involved in the antioxidant, such as heme oxygenase-1 (HO-1) (Otterbein et
al., 1999; Reddy et al., 2009; Wang et al., 2007). To determine if GAT107 can induce
the activation of Nrf2, macrophages were exposed to 24h of 95% O2 (hyperoxia) and
incubated 3.3 µM GAT107. Our results indicate that under hyperoxic conditions
(25.83 ± 7.19%), there was no significant increase in Nrf2 localization to the nucleus,
compared to macrophages exposed to room air (21.2 ± 4.8%) (Figure 7A). However,
GAT107 significantly increased Nrf2 nuclear localization (51.45 ± 4.08%, p <0.05),
compared to vehicle control (31.03 ± 5.01%) (Figure 7A). Next, we determined the
levels of the protein, HO-1 in macrophages by Western blot analysis. Under hyperoxic
conditions (0.643 ± 0.075 AU HO-1/actin), there was a non-significant change in HO1 levels when compared to 21% O2 room air (0.107 ± 0.01 AU HO-1/actin) (Figure
7B). However, the incubation of macrophages with 3.3 µM GAT107 (2.38 ± 1.91 AU
HO-1/actin, p < 0.0001) induced a significant increase in HO-1 levels, compared to
vehicle control (0.745 ± 0.05 AU HO-1/actin) (Figure 7B). These results suggest that
in vitro, GAT107 induces Nrf2 and HO-1 upregulation.
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4.8. GAT107 attenuates hyperoxia-induced mitochondrial membrane
hyperpolarization and mitochondrial superoxide accumulation
The exposure of macrophages to hyperoxia has been reported to produce
mitochondrial damage (Ma Cui et al., 2018; Pagano and Barazzone-Argiroffo, 2003).
Furthermore, mitochondrial damage has a significant inhibitory effect on
macrophage phagocytosis (Orrenius et al., 2011). To determine if 24 h of hyperoxic
exposure to macrophages affects mitochondrial function, the mitochondrial
membrane potential was determined using the tetramethylrhodamine ethyl ester
(TMRE) assay. Our results indicated that the mitochondrial membrane potential of
macrophages exposed to hyperoxia was hyperpolarized (141 ± 13.8 %, p < 0.0001)
compared to macrophages exposed to room air (100 ± 0%). Moreover, in this study,
hyperoxia-induced mitochondrial hyperpolarization was significantly attenuated by
GAT107 at 3.3 µM (62.85 ± 7.29 %, p < 0.0001) compared to vehicle control (123.5 ±
4.6%) (Figure 8A). Additionally, the prolonged exposure to hyperoxia also
significantly increased the mitochondrial levels of superoxide (mitoSOX) (212 ± 23
%, p < 0.01) when compared to macrophages that remained in room air (21% O2)
conditions (100 ± 0%) (Figure 8B). Furthermore, GAT107 treatment significantly
decreased (147.7 ± 33.4 %, p < 0.01) hyperoxia-induced increased mitoSOX levels
when compared to hyperoxia-compromised macrophages treated with vehicle
control (226.3 ± 31%) (Figure 8B). Therefore, these results suggest that GAT107
attenuates hyperoxia-induced mitochondrial membrane hyperpolarization along
with the amelioration of hyperoxia-induced mitochondrial superoxide accumulation.
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4.9. GAT107 Attenuates Hyperoxia-Compromised MnSOD Activity
Under normal cellular conditions, mitochondrial superoxide is rapidly dismutated
into hydrogen peroxide by MnSOD (Candas and Li, 2014). To determine if hyperoxiaexposure affected total levels of MnSOD protein in macrophages, Western blot
analysis was performed on whole cell lysates collected from RAW 264.7 cells exposed
to 24 h of hyperoxia and incubated with 3.3 µM GAT107 (Figure 9A), as described
previously. Interestingly, in macrophages exposed to hyperoxic conditions, there was
a significant increase in the total levels of MnSOD protein (2.93 ± 0.18 MnSOD/actin,
p < 0.001) when compared to cells that remained in room air control conditions (1.17
± 0.23 MnSOD/actin). Furthermore, incubation with 3.3 µM GAT107 had no
statistically significant effect (2.89 ± 0.13 MnSOD/actin) on hyperoxia-increased
MnSOD protein levels when compared to the vehicle control group (2.78 ± 0.15
MnSOD/actin). Therefore, we postulated that the significant increase in
mitochondrial superoxide following the prolonged exposure to hyperoxia could
result from an alteration in the activity of MnSOD.
To determine if GAT107 modulated MnSOD activity under hyperoxic conditions,
macrophage whole cell lysates were collected as previously described and subjected
to a MnSOD enzyme activity kit assay. As shown in Figure 9C, macrophages exposed
to hyperoxic conditions had a significant decrease in MnSOD activity (2.72 ± 0.11
U/mg protein, p < 0.0001) when compared to cells that remained in room air
conditions (3.9 ± 0.2 U/mg protein). Interestingly, incubation with 3.3 µM GAT107
significantly increased the MnSOD activity of hyperoxia-exposed macrophages (3.26
± 0.047 U/mg, p<0.001) when compared to macrophages treated with vehicle control

45

(2.73 ± 0.09 U/mg) (Figure 9C). Therefore, these results suggest that GAT107
attenuates hyperoxia-compromised MnSOD function through modulating MnSOD
activity independent of its whole cell protein levels.

4.10. GAT107 restores MnSOD activity by inhibiting hyperoxia-induced
MnSOD glutathionylation
Previous studies indicate that under oxidative stress conditions, MnSOD undergoes
post-translational modification and becomes less enzymatically active (Candas and
Li, 2014). MnSOD activity was not dependent on whole cell MnSOD protein levels as
GAT107 did not significantly alter MnSOD activity compared to the hyperoxia control
group (Figure 10A). Therefore, we determined the effect of GAT107 on posttranslational modification by the reversible glutathionylation of MnSOD, which
decreases MnSOD activity. Western blot analysis of co-immunoprecipitated MnSOD
indicated that macrophages exposed to hyperoxia had significant higher levels of
glutathionylated MnSOD compared those exposed to the room air control group (91.8
± 6.7 % versus 7.6 ± 4.5 % GSH/MnSOD, p < 0.0001). Macrophages exposed to
hyperoxia and incubated with 3.3 μM GAT107 had a significantly lower level of
glutathionylated MnSOD compared to vehicle control (53.5 ± 7.5 % versus 91.2 ± 6.5
% GSH/MnSOD, p < 0.01). A correlation analysis indicated a significant negative
correlation between an increase in the glutathionylation of MnSOD and MnSOD
activity (correlation coefficient, r = -0.8818, p < 0.0001) (Figure 10B).
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5. DISCUSSION
We have previously shown that treatment with the α7nAChR partial-agonist, GTS-21,
can attenuate hyperoxia-compromised bacterial clearance functions in mice with PA
lung infection (Sitapara et al., 2014), but does not significantly improve mouse
survival rates.
In this study, we demonstrate that GAT107, an α7nAChR ago-PAM, significantly
improves the survival rates of mice by attenuating hyperoxia-compromised bacterial
clearance functions of mice. The improvement of bacterial clearance functions was
caused by efficacy of GAT107 on attenuating hyperoxia-compromised macrophage
functions. The hyperoxia-impaired macrophage functions were attenuated by the
GAT107-mediated decreased oxidation of F-actin, a critical cytoskeletal component
in macrophage phagocytosis. GAT107 protected mouse lungs and macrophages from
the effects of hyperoxia by ameliorating hyperoxia-induced oxidative stress and
enhancing the antioxidant response. These effects of GAT107 on macrophages were
demarcated by improving the redox balance in mitochondria, resulting in attenuated
mitochondrial stress and the enhanced antioxidant function of MnSOD. Interestingly,
GAT107 modulated MnSOD activity via attenuation of hyperoxia-induced cysteine
glutathionylation. These results suggest that GAT107 increases bacterial clearance by
improving hyperoxia-compromised phagocytic function of macrophages via
improving the redox balance of macrophages.

5.1. The systemic administration of GAT107 increases survival in
hyperoxia-compromised mice with PA lung infection
Herein this study, we demonstrate that GAT107 administration significantly
improves the survival rates of mice exposed to hyperoxia and then challenged with
47

PA lung infection. Since 1899, it has been previously reported that in subjects exposed
to 100% oxygen tensions that it promotes the pathogenesis of pneumonia and lung
injury (Smith, 1899). PA is a ubiquitous gram-negative bacterium, which is typically
harmless, but in immunocompromised individuals, such as patients exposed to
prolonged periods of hyperoxia, PA becomes highly opportunistic and pathogenic
(Faure et al., 2018). The uncontrolled and elevated bacterial burden of PA in the lungs
leads to disruption and damage to the endothelial and epithelial alveolar barriers,
which can result in acute lung injury (ALI)/acute respiratory distress syndrome,
leading up to multiple organ failure and death (Faure et al., 2018; Sadikot et al., 2005;
M. Wang et al., 2019).
A key pathological feature characterizing hyperoxia-compromised subjects with PA
lung infection is the presence of ALI. The prolonged exposure to hyperoxia itself can
cause hyperoxia-induced acute lung injury (HALI) characterized by increased airway
protein content and inflammatory cell infiltration, which is mediated in part by both
oxidative stress and the extracellular accumulation of HMGB1 (Entezari et al., 2014;
Kallet and Matthay, 2013; Patel et al., 2020; Sitapara et al., 2020). Previously, it has
been demonstrated that activation of the cholinergic anti-inflammatory pathway can
protect against shock-induced death and lung injury in dogs by reducing
vasopermeability and TNF-α and Il-1 levels (Hu et al., 2014). Specifically, treatment
with GTS-21 has been demonstrated to have a protective effect against both
hyperoxia and LPS-induced lung injury through mitigating the pro-inflammatory
response of macrophages (Sitapara et al., 2020, 2014; J. Wang et al., 2019). Therefore,
based on the data presented in this study and others, the treatment of subjects that
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receive hyperoxic oxygen therapy, such as those under mechanical ventilation, with
activators of the cholinergic anti-inflammatory pathway like GAT107, may be
effective in alleviating lung injury and subsequently improve survival rates.
Importantly, length of mechanical ventilation days is directly associated with the
incidence of mortality in ICU patients (Pranikoff et al., 1997). Thus, the development
of treatments, like GAT107, that reduce pulmonary inflammation, lung
permeability/edema, and lung injury, may be a potential therapeutic intervention to
improve lung functions and allow clinicians to better use conservative oxygen
strategies and/or reduce the amount of days a subject requires mechanical
ventilation (Jaffal et al., 2017). However, future studies are needed to confirm
whether the ability of GAT107 to increase the survival rates of hyperoxiacompromised mice with PA lung infection is through ameliorating inflammatory lung
injury and modulating levels of HMGB1.

5.2. GAT107 Attenuates the Hyperoxia-Compromised Bacterial Clearance
Functions of Mice with PA lung infection
As previously mentioned, high levels of PA in the lungs is damaging to pulmonary
tissue, which can result in increased mortality rates in ventilated patients (Faure et
al., 2018; Sadikot et al., 2005; M. Wang et al., 2019). As shown in Figure 2, mice
subjected to the prolonged exposure to hyperoxia and challenged with PA lung
infection have an impaired capacity to clear PA in the airways and lung tissue, and
administration of GAT107 can significantly attenuate this dysfunctional host defense
response. As compared to our previous findings where 4 mg/kg i.p. of GTS-21 was
given three times a day under the same experimental paradigm (Sitapara et al., 2014),
the twice daily administration of 3.3 mg/kg i.p. of GAT107 produced a ten-fold
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improvement in the clearance of bacteria by the mice. Since agonists of α7nAChR are
prone to receptor desensitization, we hypothesized that the ago-PAM properties of
GAT107 may allow for lower and less frequent dosing to produce a similar magnitude
of bacterial clearance, but a more detailed pharmacological evaluation will be
required to verify our hypothesis. Nevertheless, these improved clinically relevant
outcomes are important because as mentioned previously, patients receiving oxygen
therapy will be exposed to hyperoxia for extended periods of times, which can
compromise innate immune responses needed to clear bacteria, increasing the
incidence of hospital-acquired infections (Kallet and Branson, 2016; Koenig and
Truwit, 2006; Mach et al., 2011; Six et al., 2016). Moreover, other investigations have
also utilized direct vagus nerve stimulation, which activates the cholinergic antiinflammatory α7nAChR’s, and has been shown to improve the bacterial clearance
functions and survival rates of subjects with sepsis (Borovikova et al., 2000; Huston
et al., 2007; Kessler et al., 2012; Wang et al., 2016). Furthermore, the major cause of
death in people with COVID-19 is fatal pneumonia mediated in part by a hyperinflammatory response (Huang et al., 2020). Current expert opinions hypothesize
that use of non-invasive vagus nerve stimulation may be a potential treatment
strategy to mitigate the hyper-inflammatory syndrome in COVID-19 (Andersson et
al., 2020; Staats et al., 2020). Therefore, the identification of novel therapeutic
strategies, such as activators of the cholinergic anti-inflammatory pathway (e.g.
GAT107, GTS-21, and vagus nerve stimulation), that restore host innate immune
function to diminish the adverse effects of pneumonia are critically needed.
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5.3. GAT107 Significantly Attenuates impaired Macrophage Innate
Immune Functions produced by hyperoxia through mitigating the
oxidation of F-Actin
Our results indicated that GAT107 significantly attenuated the hyperoxia-induced
impairment of macrophage phagocytic function in cultured macrophages and
primary BMDMs (Figure 3). Previously, we and others have reported that prolonged
exposure to hyperoxia compromises macrophage phagocytic function (Morrow et al.,
2007; Patel et al., 2013; Sitapara et al., 2014; Wang et al., 2015). Moreover, the partialα7nAChR agonist, GTS-21 (5-50µM), has been shown to restore the impaired
phagocytic function produced by hyperoxia, which was due, in part, to a decrease in
HMGB1 release from macrophages (Sitapara et al., 2014). The GTS-21-mediated
decrease in airway HMGB1 also improved bacterial clearance in the airways of mice
challenged with Pseudomonas aeruginosa (Sitapara et al., 2014). Similar to our
bacterial clearance results (Figure 2), GTS-21, at 25-50 µM (Sitapara et al., 2014), and
GAT107, at 3.3 µM, had similar efficacy in significantly attenuating hyperoxia-induced
phagocytic dysfunction of cultured macrophages, which as previously discussed, may
be due to the ago-PAM properties of GAT107 which produces greater efficacy than
the partial-agonism of α7nAChR by GTS-21. In addition, the direct stimulation of the
vagus nerve has been previously shown increase the basal and sepsis challenged
phagocytic activity of resident liver macrophages (Fonseca et al., 2019), which
suggests that activation of macrophages α7nAChR may play a critical role in
modulating intracellular pathways that mediate phagocytic activity.
Activation of neutrophil α7nAChRs with the direct agonist, nicotine, has been
demonstrated to decrease the polymerization of F-actin (Huston et al., 2009).
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Furthermore, macrophage phagocytic function is dependent upon the rapid
polymerization of F-actin filaments for migration and phagocytosis of bacteria and to
efferocytose apoptotic neutrophils (Capasso et al., 2016; Morrow et al., 2007; O’Reilly
et al., 2003; Svitkina, 2018). However, previously, our lab and others have shown that
the prolonged exposure to hyperoxia alone and in addition to PA infection, oxidizes
actin filaments, resulting in dysfunctional actin polymerization (Morrow et al., 2007;
O’Reilly et al., 2003). Antioxidants, such as procysteine and exogenous superoxide
dismutase (SOD), protect against hyperoxia-induced disorganization of the actin
cytoskeleton and attenuate phagocytic dysfunction (Morrow et al., 2007). As
demonstrated in Figure 4, GAT107 significantly ameliorated hyperoxia-induced actin
fiber disorganization by reducing the magnitude of protein oxidation. Protein
oxidation of F-actin filaments may be due to macrophage activation, which increases
superoxide production during the oxidative or respiratory burst response (Park,
2003). The respiratory burst response involves the assembly of NADPH oxidase
enzymes that generate large amounts of superoxide, which kill the ingested
pathogens (Park, 2003). However, macrophages exposed to hyperoxia for prolonged
periods of time have significantly increased intracellular levels of superoxide
(Freeman et al., 1982; O’Donovan and Fernandes, 2000; Pagano and BarazzoneArgiroffo, 2003). Consequently, hyperoxia exposure, in addition to activating
respiratory bursts, may produce excessive oxidative stress, where high levels of ROS
can induce the post-translational oxidation modifications of proteins such as actin
(Chia et al., 2019; Rudyk and Eaton, 2014; van der Vliet et al., 2018). In addition,
hyperoxia-compromised macrophages have compromised bactericidal functions to
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kill ingested PA, which may be partly due to actin disorganization and subsequent
dysfunction to assemble bactericidal enzymes or phagolysosomes (Gore et al., 2020).
Overall, our results suggest that the efficacy of GAT107 to attenuate hyperoxiacompromised macrophage function may be due, in part, to it decreasing the oxidation
of actin filaments.

5.4. GAT107 Ameliorates Oxidative Stress and Restores Antioxidant
Functions
Next, we sought to evaluate whether protein oxidation in macrophages indicated the
possible presence of an oxidative-stress response in the lungs of hyperoxiacompromised mice with PA lung infection. As demonstrated in Figure 5,
administration of GAT107 to mice decreases hyperoxia-induced increases in ORP by
increasing the total antioxidant potential in the lung tissue homogenate. In a 645person enrolled clinical trial for traumatic brain injury, a 20 mV increase in plasma
ORP levels was correlated with a 4-fold increase in mortality rates (Rael et al., 2009).
Conversely, a 1 unit increase in the inverse 1/cORP (antioxidant potential) was
correlated with 5-fold increase in mortality rates (Rael et al., 2009). Recently, we have
reported that in mice subjected to 72 h of hyperoxia, there was a significant increase
in lung lavage fluid ORP levels (Patel et al., 2020). Furthermore, 24 h of hyperoxia
exposure induces a significant increase in cultured macrophage lysate ORP levels
(Patel et al., 2016). Moreover, in both of the aforementioned studies, ascorbic acid
(50mg/kg i.p. or 1000 µM in cell culture) significantly decreased the hyperoxiainduced increases in mouse lung lavage fluid and cultured macrophage lysate ORP
levels and significantly improved animal mortality rates after challenge with PA lung
infection (Patel et al., 2020, 2016).
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As shown in Figure 6, similar to the results obtained in total lung homogenate, the
prolonged exposure to hyperoxia increased total ROS levels in macrophages and also
significantly decreased the antioxidant activity of SOD1. Our results demonstrated
that treatment with GAT107 attenuated the hyperoxia-induced increase in
macrophage ROS levels and also restored SOD1 activity. We hypothesize that
GAT107’s activation of the α7nAChR may be restoring hyperoxia-compromised SOD1
activity by transcriptional upregulation and expression of SOD1 or by altering
inhibitory post-translational regulatory modifications of SOD1 (Dinesh and Rasool,
2017). As discussed previously, prolonged exposure to hyperoxia and the activation
of macrophages induces the production of high levels of ROS such as superoxide
directly in the cytosol or indirectly by ROS leakage from the mitochondria into the
cytosol. Normally, the major antioxidant in the cytoplasm that removes superoxide is
SOD1 (Fukai and Ushio-Fukai, 2011; M. Fetherolf et al., 2017). Decreased SOD1
activity during hyperoxic conditions may therefore further affect the production and
levels of cytoplasm superoxide. As such, the cytoplasmic abrogation of elevated ROS
levels along with a compromised antioxidant defense system may then further
participate and contribute to the oxidation of macromolecules such as F-actin.
Although the exact amino acid residues in actin that are oxidized by hyperoxia remain
to be determined, biochemical analysis and computational modeling suggest that
NOX-mediated superoxide production and oxidation of actin F-actin filaments may
occur at Cys10, 217, 257, 285, and 374 (Wilson et al., 2016).
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5.5. GAT107 Activates Nrf2 and Upregulates HO-1
The GAT107-mediated restoration of the hyperoxia-induced redox imbalances may
be due to its activation of the master antioxidant pathway, Nrf2 (Figure 7). Recently,
we and others have shown that the activation of the Nrf2 pathway in macrophages in
vitro and ex vivo in mice significantly increases innate immune functions and
decreases lung injury (Cho et al., 2002; Patel et al., 2020; Reddy et al., 2009). The
activation of α7nAChR by acetylcholine or GTS-21 results in downstream Nrf2
activation and the transcriptional upregulation of the genes that produce
antioxidants such as glutathione (Hoover, 2017; Pagano and Barazzone-Argiroffo,
2003; Patel et al., 2017; Tsoyi et al., 2011; Zhang et al., 2019).
Heme oxygenase-1 (HO-1) is a Nrf2-regulated antioxidant that has been shown to
decrease oxidative-induced lung injury (Cho et al., 2002; Choi and Alam, 1996; Reddy
et al., 2009; Ryter and Choi, 2016). Under hyperoxic conditions, HO-1 null
cardiomyocytes exhibit mitochondrial damage and decreased density, which may be
due to heme toxicity (Suliman et al., 2017). Furthermore, hyperoxia exposure
increases the number of hemoproteins and free reactive iron in lung tissues of mice
(Dennery et al., 1998). It is likely that many of the free iron or heme groups found in
these

hyperoxia-compromised

subjects

are

originated

from

cytochromes,

cyclooxygenases, and other heme containing proteins found in the mitochondria
(Soares and Hamza, 2016). The accumulation of free heme in macrophages results in
heme-induced cell death characterized by damage to proteins, DNA, and lipid
peroxidation (Vijayan et al., 2018)
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HO-1 is the rate-limiting enzyme in heme metabolism, which results in the
production of approximately 86% of all carbon monoxide (Ryter and Choi, 2013;
Slebos et al., 2003). Furthermore, carbon monoxide produced by HO-1 has been
shown neutralize free iron and also activate anti-inflammatory pathways by
downregulating pro-inflammatory cytokine production (Slebos et al., 2003; Soares
and Hamza, 2016). Treatment with exogenous carbon monoxide protects against
hyperoxia-induced endothelial cell apoptosis via exerting antioxidant functions and
promoting the interaction of HO-1 with the pro-apoptotic factor, Bax (Wang et al.,
2007). Interestingly, in hyperoxic-rat models, there is minimal transcriptional
upregulation of HO-1 mRNA at 48h, and from 48h to 64h of continuous hyperoxia
exposure, there is a steady-state increase in HO-1 mRNA (Choi and Alam, 1996; Lee
et al., 1996). However, during this time, there is a substantial increase in rat mortality
rates after 60 and 72h of continuous hyperoxia (Choi and Alam, 1996; Clerch and
Massaro, 1993; Lee et al., 1996). In rats that received an HO-1 gene transfer and
exposed to hyperoxia, there were significantly improved mortality rates, lung injury,
and increased lung HO-1 mRNA and protein levels (Otterbein et al., 1999). In HO-1deficient mice with sepsis, there was a decrease in the bacterial removal by
macrophages, and this was attenuated by pretreating animals with carbon monoxidereleasing molecules (Chung et al., 2008). Conversely, it has also been shown in mice
with the disrupted or inhibited expression of HO-1 and exposed to hyperoxia, that
these mice are more protected from inflammatory lung injury and have decreased
levels of total reactive iron in the lung (Dennery et al., 2003). Thus, the exact role that
HO-1 plays in the lungs of mice and macrophages exposed to hyperoxia is not fully
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understood, but the early induction of HO-1 by GAT107 may serve as a critical
antioxidant involved in ameliorating hyperoxia-induced lung injury and improving
the innate immune response in the bacterial clearance ability by macrophages.

5.6. Hyperoxia Disrupts Mitochondrial Membrane Integrity
As demonstrated in Figure 8A, mitochondrial membrane hyperpolarization occurs in
macrophages exposed to 24 h of hyperoxia. Indeed, the hyperpolarization of
mitochondrial membrane potential in T cells precedes terminal mitochondrial
damage, resulting in cell death (Perl et al., 2004). Furthermore, mitochondrial
hyperpolarization may indicate a dysregulation of oxidative phosphorylation, which
increases ROS generation and the subsequent loss of ATP production (Chen et al.,
2017; Pak et al., 2013, p. 20). The buildup of protons in the intermembrane space due
to the inhibition of F0F1-ATPase proton motor functions can cause an electrochemical
gradient shift resulting in a hyperpolarized mitochondrial membrane potential and
the uncoupling of oxidative phosphorylation (Perl et al., 2004). As shown in Figure 8,
hyperoxia-induced about a 41% increase in mitochondrial membrane polarization,
and it has been reported that an increase of 28-32% mitochondrial membrane
potential causes ETC uncoupling, disrupted ATP generation, and significant ROS
generation (Perl et al., 2004; Skulachev, 1999). There are at least ten known sites of
physiological ROS generation in the mitochondria (Lin and Beal, 2006; Orrenius et al.,
2007; Starkov, 2008). However, it has been reported that in the presence of high
levels of oxygen, the mitochondrial flavoprotein quinone oxidoreductase may be the
sole cause of the increase in ROS levels (Hoffman and Brookes, 2009). In mice exposed
to 72 h of hyperoxia, there is a significant inhibition of complex I activity (a known
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cause of ROS generation) and decreased ATP production in isolated pulmonary
mitochondria (Ratner et al., 2009). As demonstrated in this study (Figure 8A),
GAT107 was able to significantly attenuate hyperoxia-induced macrophage
mitochondrial hyperpolarization. Therefore, through normalizing the mitochondrial
membrane potential, GAT107 is capable of mediating the maintenance of
mitochondrial integrity and thus help establish conditions that resemble normal
mitochondrial function.

5.7. GAT107 significantly attenuates the hyperoxia-induced decrease in
MnSOD activity
Under normal physiological conditions, MnSOD catalyzes the dismutation reaction of
mitochondrial superoxide into hydrogen peroxide at a rate of 2 x 109M-1s-1, which can
be then quickly converted by catalase in water (Candas and Li, 2014; Ozden et al.,
2011; Wang et al., 2018). However, as shown in Figure 9C, 24 h of hyperoxia exposure
significantly decreased MnSOD activity. Other investigations have reported that the
intermittent exposure of macrophages to hyperoxia significantly decreases MnSOD
function at 7 days, but interestingly, after 3-weeks, MnSOD function is significantly
increased (Kokubo et al., 2010). Conversely, guinea pigs exposed to hyperoxia for 3
days, alveolar macrophage MnSOD function was significantly increased (Aerts et al.,
1995). However, in cultured macrophages overexpressing MnSOD or incubated with
exogenous SOD, macrophages had significantly greater phagocytic capacity for PA
after exposure to 24h of hyperoxia (Arita et al., 2007; Morrow et al., 2007).
In our study, GAT107 restored mitochondrial function as indicated by the
normalization of mitochondrial membrane potential (Figure 8A). In addition, GAT107
also normalized mitochondrial superoxide levels (Figure 8B). The GAT107 - mediated
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normalization of mitochondrial superoxide levels were also associated with the
attenuation of hyperoxia-compromised MnSOD function (Figure 9B), suggesting that
the generation of excessive mitochondrial superoxide may result from MnSOD
dysfunction. Moreover, GAT107’s restorative effect of MnSOD function was not
dependent on the overall protein levels of MnSOD (Figure 9A). Interestingly, in
cultured macrophages exposed to 3-weeks of intermittent hyperoxia, macrophages
survived only if they express significantly higher levels of MnSOD activity (Kokubo et
al., 2010). Therefore, since GAT107 did not significantly alter the total protein levels
of MnSOD, it suggests that MnSOD activity is not being modulated MnSOD protein
levels. Thus, it is possible that GAT107 may be increasing MnSOD activity by posttranslational modifications (Ho et al., 1996).
Indeed, it has been shown that post-translational modifications of MnSOD alters its
enzymatic function (Candas and Li, 2014; Demicheli et al., 2018; Dikalova et al., 2017;
Kim et al., 2017; Patil et al., 2013; Yamakura and Kawasaki, 2010). The
glutathionylation of proteins has been reported to have a protective role against
irreversible oxidative modifications (e.g. sulfonic acid) of reactive cysteine residues
(Hurd et al., 2005; Janssen-Heininger et al., 2013). As shown in Figure 10, hyperoxia
induces the glutathionylation of MnSOD and is significantly ameliorated by GAT107
(3.3 µM) treatment. Furthermore, the increase in MnSOD glutathionylation was
significantly correlated with decreased MnSOD activity (Figure 10), demonstrating
that glutathionylation of MnSOD modulates its enzymatic activity. Previously, it has
been reported that under oxidative stress conditions, non-mitochondrial SOD1 is
glutathionylated at Cys111 and FeSOD is glutathionylation at Cys57 (Candas and Li,
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2014). Currently, it remains to be determined how GAT107 decreases the
glutathionylation of MnSOD. We postulate that GAT107 may be reducing MnSOD
glutathionylation through pathways that augment the mitochondrial antioxidant
capacity, thereby decreasing the oxidative burden on MnSOD by the GAT107-induced
activation of the Nrf2/HO-1 pathway. It may be likely that the upregulation of HO-1
can cause preferential mitochondrial translocation. In human lung epithelial cells
exposed to particulate matter 2.5 µm (PM2.5) collected from air pollution, it was
determined that there was a significant increase in preferential transposition of HO1 into the mitochondria, which may play a protective role in PM2.5 induced necrosis
(Zhou et al., 2017). It has been previously reported that the activation of α7nAChR by
acetylcholine or GTS-21 results in downstream Nrf2 activation and the
transcriptional upregulation of antioxidants such as glutathione (Báez-Pagán et al.,
2015; Hoover, 2017; Patel et al., 2017; Tsoyi et al., 2011; Zhang et al., 2019). It is likely
that under oxidative stress conditions, both non-enzymatically and enzymatically
catalyzed glutathionylation reactions occur in the mitochondria since the
mitochondrial concentration of glutathione are approximately 5-10 mM (Hurd et al.,
2005). Also, the de-glutathionylation of proteins may be facilitated by sulfiredoxins,
glutaredoxin 2 (Grx2), and thioredoxin (Trx2) (Chia et al., 2019; Findlay et al., 2006;
Janssen-Heininger et al., 2013). Thus, GAT107 could influence the deglutathionylation of proteins by acting on one of these de-glutathionylating enzymes,
although this remains to be determined. It may be likely that in hyperoxia-induced
lung injury that there is dysregulation of proteins that maintain the glutathionylation
profile of proteins since dysregulation of glutathionylation has been linked to lung
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diseases such as idiopathic pulmonary fibrosis, asthma, and chronic obstructive
pulmonary disorder (Chia et al., 2019).
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6. CONCLUSIONS
As shown in Figure 11, the α7nAChR type 2 ago-PAM, GAT107, attenuates hyperoxiainduced innate immune dysfunction of mice with PA lung infection. GAT107 restored
bacterial clearance functions of mice, in part, by mitigating hyperoxia-induced
macrophage phagocytic dysfunction. Hyperoxia exposure also oxidized F-actin
filaments in macrophages, which was reduced in cells incubated with GAT107. In
mice exposed to hyperoxia with PA lung infection, there was a significant increase in
lung oxidative stress and reduced antioxidant potentials that were attenuated by
GAT107 administration. Indeed, in macrophages, GAT107 decreased the significant
increase in intracellular ROS levels and loss of SOD1 antioxidant function produced
by hyperoxia. GAT107 appeared to mediate the aforementioned effects of hyperoxia
by activating Nrf2 and upregulating HO-1 expression. GAT107 attenuated the
hyperoxia-compromised mitochondrial function and enhanced MnSOD function.
Moreover,

hyperoxia-induces

MnSOD

glutathionylation,

which

correlates

significantly to decreased MnSOD function. Importantly, GAT107 reduces the amount
of hyperoxia-induced MnSOD glutathionylation. Therefore, GAT107 restores
mitochondrial function through modulating the glutathionylation status of MnSOD,
which may participate in regulating oxidative stress-induced macrophage
dysfunction.
Other studies have indicated that the inhibition of α7nAChR with antagonists
(methyllycaconitine and α-bungarotoxin), only partially reduces GTS-21’s efficacy to
inhibit LPS-induced secretion of IL-6 and TNFα (Garg and Loring, 2019). GTS-21 also
partially ameliorates LPS-induced secretion of both IL6 and TNFα from cultured
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macrophages where the a7nAChR gene was knocked out (Garg and Loring, 2019). In
our study, we did not determine whether the efficacy of GAT107 was due to it
selective activation of the α7nAChR. Thus, is it possible that GAT107 may interact
with non-α7nAChR targets and future studies will be required to identify these
targets. Therefore, regardless of GAT107’s mechanism of action, our results suggest
that GAT107 may be a potential therapeutic candidate for the prevention and/or
treatment of subjects with oxygen therapy - induced compromised immunity,
including patients with VAP.
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7. FUTURE DIRECTIONS
7.1. Exploring the efficacy of GAT107 on modulating hyperoxiacompromised mice and macrophages
A potential direction for future investigation is to further delineate the mechanisms
underlying

hyperoxia-induced

mitochondrial

dysfunction

in

macrophages.

Connecting these features with ETC function, ATP production, and the role of redox
imbalance via glutathionylation mechanisms is needed. Moreover, it is well
established that lung protein glutathionylation plays a critical pathological role in the
pathogenesis of lung diseases like asthma and idiopathic pulmonary fibrosis (Chia et
al., 2019; Janssen-Heininger et al., 2013), however, it would be interesting to explore
the role lung protein glutathionylation plays in hyperoxia-induced acute lung injury
and macrophage dysfunction. Since this current study established that GAT107
induces an antioxidant response in mouse lung tissue and in macrophages, it would
be interesting to explore what enzymes, such as glutathione S-transferase,
glutaredoxin, thioredoxin, and peroxiredoxins, are involved in the glutathionylation
or de-glutathionylation process of MnSOD and possible other proteins.
In these results, our lab has demonstrated that GAT107 can improve the bacterial
clearance functions of mice with PA lung infection through alleviating hyperoxiainduced macrophage dysfunction (Figure 11). Recently, our lab has shown that GTS21 can alleviate inflammatory lung injury in mice subjected to the prolonged
exposure to hyperoxia (Sitapara et al., 2020). Increased lengths of hyperoxia
exposure along with hyperoxia-induced inflammatory lung injury in combination
with PA lung infection-induced lung injury contribute to poor prognosis’ and higher
mortality rates in ventilated-associated pneumonia patients (Bassi et al., 2014;
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Oliveira et al., 2014; Rello, 2005; Spalding et al., 2017; M. Wang et al., 2019). Thus,
extending this study to determine if GAT107 ameliorates inflammatory lung injury is
needed in order to fully ascertain the efficacy of GAT107 on improving survival rates
in hyperoxia-compromised mice with PA lung infection. Indeed, inflammatory lung
injury in hyperoxia-compromised subjects with and without PA lung infection can be
attenuated via using neutralizing anti-HMGB1 antibodies to target extracellular
HMGB1 in the airways of mice (Entezari et al., 2014; Patel et al., 2013). The
accumulation of extracellular HMGB1 in the airways of mice is an important mediator
of hyperoxia’s role in compromising alveolar macrophage functions. In addition,
HMGB1’s unique pathological role may be both temporal and concentration
dependent, yielding a striking and currently under explored pleiotropic role in the
lung. Treatment with HMGB1 can directly cause macrophage dysfunction (Entezari et
al., 2012) and can stimulate the endocytosis of HMGB1 into macrophages and both
cause and contribute to a hyper-inflammatory response. Extracellular HMGB1 can
augment pro-inflammatory responses of bacterial and viral pathogens (pathogen
associated molecular patterns (PAMPS)) via the formation of HMGB1-PAMP
conjugates (Andersson et al., 2020; Lu et al., 2014). These HMGB1-PAMP conjugates
can then be endocytosed by macrophages and synergize the pro-inflammatory
response, which may be a significant contributing factor underlying the cytokinestorm syndrome in COVID-19 (Andersson et al., 2020). Thus, it would be also
beneficial to explore the role of GAT107 in ameliorating the secretion and
extracellular accumulation of HMGB1 from macrophages in the context of treating
inflammatory lung injury in oxygen-therapy treated patients, especially in COVID-19.
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7.2. Can we use α7nAChR activators like GAT107 for the treatment of
COVID-19?
The coronavirus disease of 2019 (COVID-19) caused by SARS-CoV2 is a complex
disease that has profound effects on the lung, central nervous system, circulatory
system’s clotting mechanisms, cardiac tissue, and the gastrointestinal system
(Farsalinos et al., 2020b, 2020a; Rothan and Byrareddy, 2020). As of the writing of
this dissertation, the coronavirus pandemic has approximately 13,500,000 confirmed
cases and 9350,000 confirmed deaths worldwide. Current CDC estimates have
determined that 81% of patients with COVID-19 experience mild to moderate
symptoms including shortness of breath and mild forms of pneumonia (To et al.,
2020). In addition, between 14 and 5% of patients experience severe to critically
severe COVID-19 symptoms, respectively, which includes dyspnea, hypoxia, up to
respiratory failure and multiple organ failure (To et al., 2020). In the United States,
approximately 19% of all COVID-19 patients require hospitalization, of which, 6% are
admitted to Intensive Care Units (ICU) (Li et al., 2020). Although there is a wide range
of symptoms for COVID-19 patients, around 3 to 17% of all COVID-19 patients are
diagnosed with one of the hallmarks of severe COVID-19 (N. Chen et al., 2020; Guan
et al., 2020; Huang et al., 2020; Wang et al., 2020; Wu et al., 2020; Yang et al., 2020),
which is acute respiratory distress syndrome (ARDS) that results in the need for
patients to be mechanically ventilated as a life-saving intervention (Coperchini et al.,
2020). Ultimately, of the critically severe COVID-19 patients whom are admitted into
ICUs, there is an approximate 39 to 72% mortality rate (Huang et al., 2020; Wu et al.,
2020; Yang et al., 2020).
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Early on, the clinical observations that studied COVID-19 disease progression
determined that around 14% of all patients suffer from peripheral bilateral ground
glass opacities by CT scan, which indicated that these patients were suffering with a
partial airway filling of fluids and pulmonary wall thickening and also 75% of all
patients have pneumonia (N. Chen et al., 2020). Moreover, this hallmark symptom of
lung inflammation in severe COVID-19 has recently been hypothesized to be
condition known as the “cytokine-storm”, whereby the presence of excessive levels
of pro-inflammatory cytokines exacerbate lung injury and promote multiple organ
failure (Coperchini et al., 2020).
In this brief communication, the detailed mechanisms for SARS-CoV2 induced hypercytokemia are outside of the scope of this article, but we recommend reading
Coperchini et al. (2020) for those concepts. Classically, the cytokine-storm syndrome
is mediated in part by a hyperactive response of immunomodulatory molecules that
results in high plasma levels of TNF-a, and interleukins including IL-1b, IL-8, and IL6 (Lee et al., 2014). In the context of COVID-19, 5 separate study cohorts have
reported that plasma levels of IL-6 range from 7 to 64 ng/mL in patients with severe
disease phenotypes, which has previously been thought to be a major mediator of
acute lung injury and ARDS (Sinha et al., 2020). However, as reported in 3 large cohort
lung study groups (ALVEOLI, FACT, and SAILSS), non-COVID19 patients with
diagnosed ARDS have plasma levels of IL-6 that range from 130 to 443 ng/mL in
patients with a hypoinflammatory response and up to a 578 to 1618 ng/mL in
patients with a hyperinflammatory response (Sinha et al., 2020). Although this
disparity in the role in IL-6-mediated ARDS may be evident within patient plasma
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samples compared between COVID-19 and large cohort ARDS studies exists, several
therapeutics have been developed to target IL-6 as a COVID-19 treatment strategy.
The monoclonal antibodies against Ll-6, tocilizumab and sarilumab, are being used
currently to treat the cytokine release syndrome for COVID-19 (clinical trials
NCT04306705 and NCT04322773). Currently, due to the expedited clinical trial
pipeline given to the development of these IL-6 targeted therapies and low clinical
trial populations, the US FDA has still been unable to approve use of any IL-6 inhibitor
for the treatment of COVID-19 (“Immune-Based Therapy | Coronavirus Disease
COVID-19,” n.d.; Mehta et al., 2020). Internationally, clinicians are hopeful yet
concerned about IL-6 therapies, due to the presence of several negative side effects.
For instance, IL-6 inhibitors are noted for having the ability to increase the risk and
rate of opportunistic infections (Calabrese et al., 2020). Moreover, clinically relevant
models that simulate the use of oxygen therapy for prolonged periods of time, such
as in those individuals receiving treatment for COVID-19, that the overexpression of
IL-6 is protective against oxygen-induced lung injury in mice (Ward et al., 2000).
Thus, it is still unclear what definitive role IL-6 is playing in COVID-19, which has been
a catalyst for other investigations to continue searching for other possible therapeutic
targets.
Recent epidemiological evidence shows that based on Chinese clinical trials, that
smokers (N = 159 people) are statistically less likely to be hospitalized due to COVID19 (total N = 1623 people) (Gonzalez-Rubio et al., 2020; Polosa and Caci, 2020).
Moreover, non-peer reviewed clinical observations in France found that patients that
are current smokers (<5% of all COVID-19 patients) are protected against SARS-CoV2
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pathophysiology (Changeux et al., 2020). Although these studies and others have
been steeped in hotly contested debate, the general conclusions definitively state that
smoking tobacco is incredibly harmful, but perhaps the inhaled nicotine, with can be
found in tobacco smoke, may have efficacious effects on ameliorating COVID-19
symptom severity. Indeed, nicotine as an anti-inflammatory molecule has been long
recognized as an activating molecule of the cholinergic anti-inflammatory pathway
(Pavlov et al., 2003; Scott and Martin, 2006).
Between the clinical data showing a possible link between COVID-19 disease severity
and the exacerbated lung injury induced by SARS-CoV2 hyper-cytokemia (a.k.a. the
cytokine-storm), COVID-19 has been postulated to be a disease of the cholinergic antiinflammatory pathway (Andersson et al., 2020; Farsalinos et al., 2020a; GonzalezRubio et al., 2020; Mazloom, 2020). The fundamental underpinning of this theory lies
in the COVID-19-induced imbalance in control of cytokine secretion, which normally
is maintained via vagus nerve mediated cholinergic signaling.
The cholinergic anti-inflammatory operates by the afferent vagus nerve sensing the
presence

of

pathogens,

damage-associated

molecular

patterns,

and

cytokines/chemicals. The afferent vagus nerve then signals to the central nervous
system, and then communicates via the efferent vagus nerve to effector organs. At
least in the lung, neuroendocrine cells receive effect vagus nerve innervations that
form the parasympathetic nervous system relay (Wu et al., 2014). Activation of these
pulmonary neuroendocrine cells found in the distal airways induces the release of
acetylcholine, which can modulate the local inflammatory environment by binding to
and activating the α7 nicotinic acetylcholine receptor (α7nAChRs) on alveolar
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macrophages (Borovikova et al., 2000; Pavlov et al., 2003; Wang et al., 2003; Wu et
al., 2014).
As previously mentioned, COVID-19 patients experiencing symptoms ranging from
shortness of breath, hypoxemia, ARDS, and respiratory failure, receive some form of
either non-invasive or invasive mechanical ventilation oxygen therapy. However, it is
unclear whether the lung injury in COVID-19 patients is purely due to normal viral
pathogenesis, patient induced lung injury (Fan et al., 2020), or exacerbated by the
oxygen therapy itself. In clinically relevant laboratory models that simulate the use of
oxygen therapy, the prolonged exposure to high concentrations of oxygen can directly
cause injury to the lungs (Entezari et al., 2014; Patel et al., 2020; Ward et al., 2000).
Moreover, these models of hyperoxia-induced inflammatory lung injury also can
retain the cytokine-storm syndrome similar to what is observed in COVID-19
patients. In subjects with hyperoxia-induced inflammatory lung injury, the systemic
administration of a small molecule called GTS-21, activates the α7nAChR-mediated
cholinergic anti-inflammatory, which results in attenuated lung injury in mice
(Andersson et al., 2020; Sitapara et al., 2020).
GTS-21 mediated the amelioration of inflammatory lung injury by significantly
reducting both plasma and airway levels of the damage associated molecular pattern,
high mobility group box-1 (HMGB1) (Sitapara et al., 2020). Importantly, increased
plasma levels of HMGB1 have recently been shown to be significantly correlated with
more severe clinical COVID19 outcomes that result in the increased ICU
hospitalization and death rates (L. Chen et al., 2020). As such, use of therapeutics that
activate the α7nAChR-mediated cholinergic anti-inflammatory pathway like nicotine
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or GTS-21, that decrease the secretion of HMGB1 may be critical in preventing COVID19 patients from severe disease complications.
HMGB1 as a target for treating COVID-19 has recently gained more attention. In other
disease models, extracellular HMGB1 has been shown to form complexes with viral
and bacterial pathogen, and damage associated molecules (Andersson et al., 2020; L.
Chen et al., 2020). HMGB1 complexes are then endocytosed via RAGE receptors on
innate immune cells, such as macrophages. Internalized HMGB1-complexes then can
activate cytosolic receptors that activate inflammasome and cell death pathways
(Andersson et al., 2020; Lu et al., 2014). It is hypothesized that HMGB1 can form
complexes with SARS-CoV2 RNA fragments, which can then be up taken into innate
immune cells to further exacerbate the host innate hyper-inflammatory response to
SARS-CoV2 infection (Andersson et al., 2020). Moreover, activation of macrophage
α7nAChR’s with small molecule agonists (acetylcholine and GTS-21), have been
shown to inhibit the activation of inflammasomes via attenuating the endocytosis of
HMGB1-LPS complexes into the cell (Lu et al., 2014; Yang et al., 2019).
Recent epidemiological studies have demonstrated that men and women have similar
prevalence rates for COVID-19, but however, men are statistically more susceptible
to severe COVID-19 symptoms and higher mortality rates (Jin et al., 2020). In
pulmonary arterial hypertension patients, men have higher mortality rates, which
was found to be to an increased level of pulmonary vascular necrosis and an increased
amount of HMGB1 released into the extracellular milieu (Rafikov et al., 2019;
Zemskova et al., 2020). Therefore, HMGB1 may be a possible contributing mechanism
to explain why men with COVID-19 have higher mortality rates than compared to
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women. Therefore, activation of the cholinergic anti-inflammatory pathway with
α7nAChR activators has 2 hypothetical main modes of protection against SARS-CoV2
infection: 1) through the attenuation of SARS-CoV2 induced hyper-cytokemia,
especially HMGB1, and by 2) inhibiting HMGB1-SARS-CoV2 RNA complexes that
further exacerbate the hyper-inflammatory response.
In addition, in silico-based investigations have discovered a potential interaction
between the α7nAChR and the SARS-CoV2 glycoprotein spike protein (Farsalinos et
al., 2020b). Indeed, the interaction between α7nAChR and the spike protein was
within the same magnitude as alpha-bungarotoxin, the snake venom derived
molecule that selectively antagonizes the α7nAChR (Farsalinos et al., 2020b). Thus, it
was hypothesized that this interaction may play a critical role in disrupting the
cholinergic anti-inflammatory system for COVID-19 patients, and it may explain of
why severe COVID-19 patients present severe ARDS and lung inflammation.
Currently, there is conflicting data on whether nicotine’s role in modulating the
expression of angiotensin 2 receptor (ACE2) is protective or harmful in SARS-CoV2
infection (C et al., 2020; Simons et al., 2020; Tindle et al., 2020). Depending on the
organ and cell-type, nicotine has pleiotropic effects on ACE2 receptor expression
(Leung et al., 2020; Tindle et al., 2020). The ACE2 receptor is the primary entry-point
by which SARS-CoV2 infiltrates the cell. However, in silico molecular docking studies
have revealed that nicotine may bind to ACE2 and competitively inhibit the ACE2SARS-CoV2 complex (C et al., 2020). Therefore, although nicotine may have a
potential role in mediating SARS-CoV2 cell invasion, nicotine has a well-established
potent anti-inflammatory property that may be useful in the treatment or prevention
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of COVID-19 associated ARDS. Nicotine, under the strict supervision and guidance of
a physician, may then therefore be a potential therapeutic strategy in conjunction
with palliative care, anti-virals, antibiotics, and antibodies for COVID-19, if used
under heavily controlled conditions.
Given the wide availability commercially for nicotine containing products, their
affordable manufacturing cost, and a range of delivery routes that can be tailored to
meet individual patient needs, nicotine has then been thought to be a likely potential
treatment in conjunction with anti-virals, antibodies, and antibiotics for the
treatment of COVID-19. As a disclaimer, the use of tobacco products is known to cause
cancer and increases the susceptibility to infections, so only under the strict
supervision of a physician-guided treatment strategy should nicotine ever be
potentially considered for the treatment of any disease.
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